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Multi-residue analysis of drugs of abuse in wastewater 
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chromatography-positive electrospray ionisation tandem 
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A new-multi residue method was developed for the environmental monitoring of 65 stimulants, opiod 
and morphine derivatives, benzodiazepines, antidepressants, dissociative anaesthetics, drug precursors, 
human urine indicators and their metabolites in wastewater and surface water. The proposed analytical 
methodology offers rapid analysis for a large number of compounds, with low limits of quantification 
and utilises only one solid-phase extraction-ultra performance liquid chromatography-positive 
electrospray ionisation tandem mass spectrometry (SPE-LC-MS/MS) method, thus overcoming the 
drawbacks of previously published procedures. The method employed solid phase extraction with the 
usage of Oasis MCX sorbent and subsequent ultra-performance liquid chromatography-positive 
electrospray ionisation tandem mass spectrometry. The usage of a 1.7 µm particle size column (1 x 150 
mm) resulted in very low flow rates (0.04 mL min
-1
), and as a consequence gave good sensitivity, low 
mobile phase consumption and short retention times for all compounds (from 2.9 to 23.1 min). High 
SPE recoveries (>60 %) were obtained for the majority of compounds. The mean correlation 
coefficients of the calibration curves were typically higher than 0.997 and showed good linearity in the 
range 0 – 1000 µg L-1. The method limits of detection ranged from 0.1 ng L-1 for compounds including 
cocaine, benzoylecgonine, norbenzoylecgonine and 2-oxo-3-hydroxy-LSD to 100 ng L
-1 
for caffeine. 
Method quantification limits ranged from 0.5 to 154.2 ng L
-1
. Intra- and inter-day repeatabilities were 
on average less than 10 %. The method accuracy range was within -33.1 to 30.1 %. The new multi-
residue method was used to analyse drugs of abuse in wastewater and river water in the UK 
environment. Of the targeted 65 compounds, 46 analytes were detected at levels above the method 
quantification limit (MQL) in wastewater treatment plant (WWTP) influent, 43 in WWTP effluent and 
36 compounds in river water. 
KEYWORDS: illicit drugs, drugs of abuse, precursors, UPLC, wastewater, surface water, environment, 
LC-MS/MS, sewage, crack cocaine, SPE, pharmaceuticals, multi-residue 
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1. INTRODUCTION 
Abuse of both illicit drugs and legally prescribed drugs is a significant problem in societies across the 
world. Due to the quantity of these compounds produced and consumed, they are now established as 
emerging environmental contaminants. Drug residues reach natural surface waters primarily due to the 
insufficient removal of these compounds at wastewater treatment plants. These residues are present in 
the sewage water due to excretion of pharmacologically active compounds by humans after 
consumption; mainly via urine or faeces, and also due to the direct disposal of drug compounds from 
households into the sewage system. 
Currently, the presence of abused compounds in the environment has been studied to a somewhat 
limited extent, with few publications detailing relatively comprehensive monitoring results for 
detection of illicit/abused drugs in surface water and/or wastewater [1-8].
 
As observed for some 
pharmaceuticals, for example diclofenac and fluoxetine [9], the presence of compounds in the 
environment that have been specifically designed to have an impact on humans can also have a negative 
impact on ecosystems, even at relatively low concentrations. Therefore, research into the presence of 
these biologically active compounds in the environment is vital in order to improve knowledge on the 
occurrence, fate and exposure of these compounds and their potential impact on aquatic and human life.  
According to statistics from the United Nations Office on Drugs and Crime ‘World Drug Report 
2008’ [10], there were an estimated 208 million illicit drugs users in the last year, with 26 million users 
considered severely drug dependant. Official statistics for this so called ‘hidden’ problem are currently 
generated mainly through the use of population surveys, as well as indicators such as medical figures 
and crime statistics [10,11]. However, as the information is collected mainly from the drug users 
themselves, data generated may be inaccurate, estimates are difficult to compare between different 
communities and due to the time consuming nature of population surveys new trends cannot be 
monitored rapidly [12]. Therefore, as recently recommended by the Commission on Narcotic Drugs of 
the United Nations [13]  a novel approach is needed in order to provide more accurate and comparable 
drug estimates, as well as providing these estimates more rapidly in order to detect changing drug 
trends. 
With this in mind, an approach to provide direct quantitative estimates, in a non-invasive manner and 
in almost real-time was first suggested by Daughton in 2001 [14] and later put into practice for the first 
time by Zuccato and co-workers in 2005 [15] to estimate cocaine consumption. This approach is based 
on the assumption that the concentration of drug residues in wastewater, before treatment, is 
proportional to the quantity of drug consumed by the local population from which the wastewater 
originated. The potential and limitations of this monitoring approach are discussed in a recent 
EMCDDA report [16] and a review by van Nuijs et al [17].  
Liquid chromatography coupled with tandem mass spectrometry is the method of choice for the 
analysis of drugs of abuse in the aqueous environment due to the high signal to noise ratio and the 
selectivity offered [3,18-32]. The majority of recently published papers now employ the use of smaller 
particle size columns, termed UPLC or UHPLC depending on manufacturer, and provide well 
established advantages in terms of sensitivity, speed of analysis and resolution of analytes compared to 
HPLC. Recently, Kasprzyk-Hordern et al. [33] were able to determine R- and S- enantiomers of several 
amphetamines, ephedrines and venlafaxine in the aqueous environment simultaneously using a chiral 
HPLC column, albeit with relatively long run times. All environmental papers published employ off-
line SPE for the concentration and clean-up of samples.  An exception to this is the work by Postigo  et 
al. [19] in which online SPE was utilised and the work by Chiaia et al [27] and Berset et al [30] in 
which large volume injection replaced the need for SPE.  
 From an analytical perspective the methods published to date have been fit for purpose and have 
successfully monitored the concentration of target residues in the environment. However the analytical 
methods published to date suffer from limitations; in terms of studying a relatively small number of 
compounds, with all methods studying 23 compounds or less [3,18-32]. Additionally, some methods 
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have further shortcomings, requiring more than one LC column [27], more than one LC mobile phase 
[18,27], more than one SPE sorbent [19] and more than one sample diluent [26,27].  
In this context, the main objectives of this work were: 
(1) To present a new, fast and sensitive analytical method for the detection of abused compounds 
overcoming many of the limitations of previous work, including (i) the use of one SPE procedure (ii) 
one LC method and (iii) reconstitution of sample in one diluent.  
(2) To incorporate a greater number of compounds into the methodology in order to improve the 
value of results, understanding of concentration levels in the environment and the cost-effectiveness of 
each sample.  
(3) To apply the validated method to river water and sewage water in various locations in order to 
collect the first comprehensive results from the UK. 
This method is the first to provide simultaneous analysis of this quantity of drugs of abuse. This 
includes eight compounds (anhydroecgonine methyl ester, ecgonidine, methcathinone, 3,4-
(methylenedioxyphenyl)-2-butanamine (BDB), mescaline, norbuprenorphine, benzoylpiperazine (BZP) 
and trifluoromethylphenylpiperazine (TFMPP)) that to the authors’ knowledge have been analysed in 
the aqueous environment for the first time. Among the compounds studied are stimulants, opiod and 
morphine derivatives, benzodiazepines, antidepressants, dissociative anaesthetics, drug precursors, 
human urine indicators and associated metabolites. In addition, the proposed analytical methodology 
offers rapid analysis for a large number of compounds, with low limits of quantification and one 
extraction and one LC method, thus overcoming the drawbacks of previously published procedures.  
2. EXPERIMENTAL  
2.1 Chemicals and materials 
Analyte names, CAS number, molecular formula, log Kow, pKa and supplier are shown in Table S1. 
All standards and internal standards were of the highest purity available (>97 %). Mobile phase 
solvents and additives were all of LC-MS quality and purchased from Sigma-Aldrich, with the 
exception of H2O which was purchased from Fisher. Hydrochloric acid (37 %), 5 % 
dimethylchlorosilane (DMDCS) in toluene and ammonium hydroxide (30 %) were purchased from 
Sigma-Aldrich. 
Surrogate/internal standards were purchased from LGC (UK), at a purity >97 %, as solutions in 
methanol or acetonitrile at a concentration of 1 or 0.1 g L
-1
: amphetamine-d11, methamphetamine-d14, 
nicotine-d4, buprenorphine-d4, diazepam-d5, heroin-d9, cocaine-d3, fentanyl-d5, codeine-d6, 
ketamine-d4, fluoxetine-d6, propoxyphene-d11, oxycodone-d6, norpropoxyphene-d5, MDMA-d5, 
oxazepam-d5, mescaline-d9, PCP-d5, morphine-d6, benzoylecgonine-d8, LSD-d3, methadone-d9, 
EDDP-d3, methaqualone-d7, dihydrocodeine-d6, MBDB-d5, cocaethylene-d8, MDEA-d5, temazepam-
d5, and MDA-d5. Caffeine-d9 was purchased from Sigma-Aldrich. All surrogate/internal standards 
were added to samples before extraction and were used for the quantification of samples. 
Individual stock solutions were purchased or prepared from powdered substance in either acetone or 
methanol at a concentration of 1 or 0.1g L
-1
 and stored in the dark at -20 °C. Mixed standard solutions 
were prepared at 10 mg L
-1
 in methanol and diluted as necessary to prepare working solutions on a daily 
basis.  The surface of glassware was deactivated in order to minimise loss of polar compounds through 
absorption onto –OH sites present on the surface of glass. The procedure to deactivate the glassware 
consisted of rinsing (once) with reagent (5 % DMDCS/toluene) for 15 seconds, toluene (twice) and 
finally methanol (thrice). 
Different water and wastewater samples were used for method development and validation. These 
were: 
- UHQ water: ultra-high quality water (UHQ-PS, ELGA, UK), 
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- surface water: collected in Marsden (UK) close to the source of the river Calder and before 
discharge from industry or treatment plants, 
- WWTP wastewater: wastewater influent and effluent collected from a treatment plant within the 
UK in April 2010 (population served 308,000, flow 55296 m
3
 day
-1
). 
2.2 Sample collection and preparation 
All samples were collected in amber silanised bottles with Teflon faced caps (Fisher, UK). River 
water and wastewater samples were vacuum filtered, firstly through GF/D 2.7 µm glass fibre filter 
(Whatman, UK) and subsequently through GF/F 0.7 µm glass fibre filter (Whatman, UK). After 
filtration, samples were acidified with 31 % HCl to pH 1.8 – 1.9. Samples were stored in the dark at 4 
°C and extracted within 20 hours. Grab samples were collected from 7 WWTP and 6 river locations 
and transported back to the laboratory in a dark and iced cool box. 
2.3 Solid-phase extraction  
Solid phase extraction (SPE) of samples was carried out with Gilson SPE, Aspec XL4 (Anachem, 
UK). A TurboVap LV concentration workstation (Caliper, UK) was utilised for evaporation of SPE 
extracts. The method was optimised through several preliminary experiments involving the following 
variables: type of sorbent, sample volume, elution conditions, evaporation temperature and filter 
membrane prior to LC-MS/MS injection.  
Initially the efficiency of various different sorbents was assessed, including: Isolute, HCX, 200 mg 
(Kinesis, UK); Oasis HLB, 60 mg (Waters, UK); Oasis MCX, 60 mg (Waters, UK); Chromabond 
C18ec, 200 mg (Anachem, UK); Supelclean ENVI-Carb, 250 mg (Sigma, UK) and Isolute ENV+, 100 
mg (Kinesis, UK). After selection of sorbent, Oasis MCX, sample volume was optimised by assessing 
the extraction efficiency of spiked river water matrix (sample volumes 100 – 250 mL for wastewater 
and 250 – 1000 mL for river water). The loss of analytes during the evaporation step (temperatures 30, 
35, 40, 45, 50 °C) and as a result of the usage of silanised/non-silanised tubes was also evaluated to 
ascertain whether the loss of analytes during the SPE procedure was caused by low SPE recovery, 
evaporation, or due to interactions of basic analytes with –OH groups present on glass surfaces. Several 
0.2 µm filter membranes prior to LC injection were also investigated: Phenex – RC, PTFE, NY 
(Phenomenex, UK); Millex – LG, GV (Millipore, UK) and Whatman – PTFE (Whatman, UK). 
The final SPE procedure was as follows. Initially the Oasis MCX was conditioned with MeOH (2 
mL) and equilibrated with 2%HCOOH/H2O (2 mL, pH 2) both at a flow rate of 3 mL min
-1
. Acidified 
river water (500 mL), wastewater influent (100 mL) or effluent (100 mL) were spiked with 50 ng of 
each surrogate/internal standard (except amphetamine-d11, nicotine-d4 and temazepam-d5 at 75 ng; 
heroin-d9 and morphine-d6 at 150 ng; norpropoxyphene-d5 and fluoxetine-d6 at 100 ng and mescaline-
d9 at 62.5 ng) and then passed through the MCX cartridge at a rate of 6 mL min
-1
. Immediately 
following loading, cartridges were washed with 2%HCOOH/H2O (2 mL, pH 2) at a flow rate of 3 mL 
min
-1 
and subsequently wrapped in aluminium foil and stored at –20 °C no longer than one week before 
being eluted. Cartridges were washed with 0.6%HCOOH/MeOH (2 mL, pH 2) at a flow rate of 3 mL 
min
-1 
followed by elution with 7%NH4OH/MeOH (3 mL) at a flow rate of 1 mL min
-1
 into silanised 
vials. Extracts were evaporated to dryness (40 °C, N2, 2-10 psi) and reconstituted with 
0.3%CH3COOH/5%MeOH/H2O (500 µL). All samples were filtered through 0.2 µm PTFE filters 
(Whatman, Puradisc, 13 mm) before being transferred to maximum recovery deactivated vials with 
PTFE septa (Waters, UK).   
SPE recoveries for studied compounds in UHQ water, surface water and wastewater were calculated 
as the ratio of the analyte peak area in the sample extract spiked before extraction with analytes (the 
peak area of analyte in unspiked sample extract was subtracted) to the analyte peak area in the non-
extracted standard solution. SPE recoveries were determined at environmentally relevant 
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concentrations: in UHQ water, WWTP effluent and WWTP influent concentrations studied were 100, 
500 and 1000 ng L
-1
, and in surface water concentrations determined were 20, 100 and 200 ng L
-1
. 
2.4 Ultra performance liquid chromatography - tandem mass spectrometry 
2.4.1 Ultra performance liquid chromatography 
Analyses were carried out with the usage of Waters ACQUITY UPLC
TM
 system (Waters, UK) 
consisting of ACQUITY UPLC
TM
 binary solvent manager and ACQUITY UPLC
TM
 sample manager. 
Several parameters were investigated to improve peak shape and resolution, and also to improve ESI+ 
performance. 
Preliminary investigations involved the usage of three different columns at various flow rates, 
ranging from an initial pressure of 3000 psi to a maximum initial pressure of 10000 psi, and 
temperatures of 30, 40 and 50 °C. The columns evaluated were all ACQUITY UPLC BEH C18, 1.7 
µm, columns (Waters, UK), with the following dimensions; 2.1 mm x 100 mm, 1 mm x 100 mm and 1 
mm x 150 mm. Other LC parameters studied included: injection volume and mobile phase 
composition. The first mobile phase tested was gradient water/methanol. However, this composition 
caused broad peak shapes and poor separation for nearly all compounds. To solve this issue, several 
additives were investigated including acidic compounds: acetic acid and formic acid; and basic 
additives ammonium acetate and ammonium hydroxide. 
The final UPLC method employed mobile phase A (pH 2.9): 79.7%H2O, 20%MeOH, 
0.3%CH3COOH and mobile phase B (pH 3.30): 99.7%MeOH, 0.3%CH3COOH. The gradient 
programme was a follows: 0min-100%A, 17min-41.3%A, 17.2min-0%A, 20.2min-0%A, 20.3min-
100%A, 34.0min-100%A. An injection volume of 20 µL was injected into the system. The column, an 
AQUITY UPLC BEH C18 (1.7µm; 1 mm x 150 mm), was maintained at 30 °C and the temperature of 
the sample manager was 4 °C. The flow rate was 0.04 mL min
-1
, which gave an initial pressure of 
~6500 psi. 
2.4.2 Mass spectrometry 
A triple quadrupole mass spectrometer (TQD, Waters, UK) with an orthogonal electrospray 
ionisation (ESI) source Z-spray was used. Analysis was performed in positive mode with an optimised 
capillary voltage of 3 kV, source temperature of 150 °C and a desolvation temperature of 400 °C. A 
cone gas flow of 100 L h
-1
 and desolvation gas flow of 550 L h
-1
 were selected. Nitrogen, used as a 
nebulising and desolvation gas, was supplied by a high purity nitrogen generator (Peak Scientific, UK). 
Argon (99.999%) was used as a collision gas. Argon pressure in the collision cell was maintained at 
2.5e
-3
 mbar.  
The mobile phase flow rate of 0.04 mL min
-1
 was directly introduced in the ion source without 
splitting. The mass spectrometer was operated in the multiple reaction monitoring (MRM) mode, 
measuring the fragmentation of the protonated pseudo-molecular ions of each compound. Data 
acquisition was carried out with the use of time windows, with an optimised dwell time of 20 ms per 
ion pair. 
The choice of fragmentation ion for each compound was based on the most intense signal. The 
optimisation of cone voltages and collision energies was made individually for each compound by 
infusion of 100 µg L
-1
 standards into the stream of mobile phase. Mobile phase flow was 0.05 mL min
-1 
and the syringe pump introduced the sample at 15 µL min
-1
. All 100 µg L
-1
 standards were prepared by 
spiking stock solution into methanol. 
 6 
2.5 Quantification and method validation  
Each compound was quantified by MRM, with the protonated molecular ion employed as the 
precursor. The most abundant transition product ion was typically used for quantification with a second 
transition, for nearly all compounds, used for confirmation. 31 deuterated internal standards were used 
to compensate for signal suppression or enhancement of analytes in the ESI source and low SPE 
recoveries. Table S2 shows the corresponding surrogate/internal standard used for each compound. A 
deuterated internal standard for all analytes was not possible due to lack of commercial availability, 
hence an internal standard that was similar in structure and gave similar analytical responses was 
selected as a surrogate for those compounds. 
Instrumental validation parameters: linearity and range, accuracy, instrumental precision, 
instrumental detection and instrumental quantification limits (IDL and IQL, respectively) were 
determined using spiked sample diluent (0.3%CH3COOH/5%MeOH/H2O). Method quantification and 
detection parameters: linearity and range, accuracy, precision of analytical method, method detection 
and method quantification limits (MDL and MQL, respectively) were determined using surface water 
and wastewater spiked with known concentrations of analytes and then extracted according to the 
procedure described in section 2.3.  
15-point multi-component internal standard calibration curves were prepared in surface water spiked 
before extraction and used for the quantification of environmental samples. The calibration curve was 
prepared by calculating the ratios between the peak area of each substance and the peak area of the 
internal standard. Masslynx 4.1 software was used to analyse and process all data. 
Linearity and range of the analytical method were determined by serial dilution of a stock solution of 
compounds (10 mg L
-1
). Sample diluent was spiked at concentrations typically found after extraction: 0 
- 1000 µg L
-1
 of each compound, apart from creatinine which due to the high levels present in the 
environment was measured from 0 – 7500 µg L-1. Surface water spiked before extraction was also 
spiked at concentrations typically found in the environment: 0 - 1000 ng L
-1
 of each compound, apart 
from creatinine which due to the high levels present in the environment was measured from 0 – 7.5 µg 
L
-1
. 
Accuracy of the method was assessed as the percentage of deviation from the known amount of 
analyte added to the sample. Precision was evaluated as the relative standard deviation (RSD) of 
replicate measurements. Both intra- and inter-day reproducibilities of the analytical method were 
assessed. 
Instrumental intra-day precision was determined over a short period of time under the same 
instrumental conditions. Twenty-four determinations covered four concentrations (0.5, 50, 500 and 
1000 µg L
-1
) in sample diluents, six replicates of each. Instrumental inter-day precision was verified by 
determinations that covered four concentrations (5, 50, 500 and 1000 µg L
-1
) in sample diluent, three 
replicates on three different days. 
Intra-day precision of the analytical method was evaluated over a short period of time under the same 
instrumental conditions. Nine determinations covered three concentrations (0.5, 50 and 1000 ng L
-1
) of 
surface water spiked before extraction, three replicates each. Inter-day precision of the analytical 
method was verified by determinations that covered three concentrations (0.5, 50 and 1000 ng L
-1
) of 
surface water spiked before extraction, three replicates each analysed on three different days. 
Quantification and detection limits were determined using a signal-to-noise approach. Standard 
solutions diluted with sample diluents (0.3%CH3COOH/5%MeOH/H2O) were used for instrumental 
detection and instrumental quantification limit determinations (IDL and IQL, respectively). Surface 
water spiked before extraction was used for method detection and method quantification limit 
determinations (MDL and MQL, respectively). The detection limit was selected as the concentration of 
compound that gave a signal-to-noise ratio of 3:1. The quantification limit corresponded to the 
concentration of compound that gave a signal-to-noise of 10:1. Method detection limits (MDLcalc) and 
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quantification limits (MQLcalc) for wastewater influent and effluent were calculated using Eqs. (1) and 
(2) respectively: 






CF x Rec
100 x IDL
 = MDLcalc
                      
(1) 






CF x Rec
100 x IQL
 = MQLcalc
                
(2) 
where: IDL is the instrumental detection limit (ng L
-1
), IQL is the instrumental quantification limit 
(ng L
-1
), Rec is the absolute recovery of the analyte (%) in matrix, and CF is the concentration factor, 
which in this method denotes 200 for wastewater. 
3. RESULTS AND DISCUSSION 
3.1 Choice of compounds  
A total of 65 stimulants, opiod and morphine derivatives, benzodiazepines, antidepressants, 
dissociative anaesthetics, drug precursors and human urine indicators were selected and incorporated 
into the method. This includes eight compounds (anhydroecgonine methyl ester, ecgonidine, 
methcathinone, 3,4-(methylenedioxyphenyl)-2-butanamine (BDB), mescaline, norbuprenorphine, 
benzoylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP)) that to the authors’ 
knowledge have been analysed in the aqueous environment for the first time.  
The range of illicit drugs selected was based mainly on their usage from UK [34,35], Europe [36] and 
global statistics [10]. Abused prescription compounds were chosen based on their reputation/potential 
for abuse [37-39] and prescription data in England [40]. Also selected were a range of metabolites that 
are excreted in man after the parent drugs are consumed. The inclusion of both parent compound and 
metabolite gives the possibility, if the parent compound is extensively metabolised, of distinguishing 
between a drug which has been consumed and a drug which has been directly disposed.   
For the first time, to the authors’ knowledge, a method has been developed to monitor the aqueous 
environment to potentially differentiate the use of powder cocaine (intranasal or intravenous) to that of 
crack cocaine (smoked). Crack cocaine, when smoked, causes the thermal degeneration of cocaine into 
many compounds including anhydroecgonine methyl ester (AEME) [41-44]. Thus, when crack cocaine 
is smoked AEME will be inhaled. AEME is subsequently metabolised in the body to ecgonidine (ECD) 
[42-44]. The powdered form of cocaine cannot be vaporized or smoked to create euphoric effect [44]. 
Both AEME and ECD are excreted mainly in the urine, with average concentration levels according to 
one study of cocaine users of 341 and 3030 ng mL
-1
 respectively (AEME was detected in 457 samples 
and ECD in 540 sample out of 730 samples that tested positive for cocaine) [44]. AEME and ECD have 
been shown to be suitable for forensic urine testing to determine crack cocaine use [44]. AEME has 
been detected in urine after intranasal or intravenous administration of cocaine [41].  
Ephedrine, pseudoephedrine and norephedrine, which are amphetamine and methamphetamine drug 
precursors were monitored in an attempt to develop a method which could potentially indicate drug 
manufacture in a local area. Although all three of these compounds have legal uses, such as in 
bronchodilators and nasal decongestants, their distribution is highly regulated around the globe [45].  
Human urine indicators continine, 1,7-dimetylxanthine and creatinine were measured in order to 
potentially use these compounds to index mass loads. This could overcome variables in drug estimation 
with regards to fluctuating population numbers and dilution of wastewater samples. Creatinine was 
used to index loads of illicit drugs by Chiaia and co-workers [27].  
 8 
3.2 UPLC-MS/MS Method Optimization 
In LC-MS/MS an efficient separation is desired in order to minimise matrix effects and improve 
sensitivity. In order to optimise chromatographic performance (reduction of peak tailing and better 
resolution) and increase response with ESI+, different mobile phases were investigated containing 
several different basic and acidic additives (see section 2.4.1). Acidic additives are known to promote 
protonation of basic compounds [23,46]  thus an increase in signal is observed in ESI+, which was also 
the case in this work. Acetic acid at a concentration of 0.3 % was selected as the optimal mobile phase 
additive due to increased sensitivity, good separation and good peak shapes.     
Sufficient chromatographic separation was obtained with an AQUITY UPLC BEH C18 column (1.7 
µm; 1 mm x 150 mm) at 30 °C and with relatively simple gradient (see section 2.4.1). Separation was 
not achieved between ephedrine and pseudoephedrine, and due to these two compounds possessing 
identical MRM transitions they were quantified as one, as previously reported by Postigo et al [19]. In 
order to separate ephedrine and pseudoephedrine chiral chromatography has to be applied [33]. 
Chromatograms of WWTP influent spiked with analytes before extraction are presented in Fig 1. The 
usage of a column with a small particle size, a small internal diameter and long length allowed for the 
establishment of low mobile flow rates (0.04 mL min
-1
) and short retention times (from 2.9 to 23.1 
min) for all compounds and internal standards analysed. High speed of analysis, simplicity of the 
gradient, and low mobile phase consumption are some of the advantages of the method. As a result a 
fast and cost effective method was developed. 
The ESI+ parameters were optimised as discussed in section 2.4.2, with final operational conditions 
compiled in Table S2. All compounds showed maximum sensitivity in positive ionisation mode, with 
the response from analytes varying significantly due to the different functionalities present in the 
molecules. Data acquisition was carried out in MRM with two transition ions, one for quantification 
and one for confirmation. In this manner, the method fulfilled EU guidelines with four identification 
points for the confirmation of analytes with LC-MS/MS detection [47]. Additionally, the ratio between 
the two transitions was used as an identification criterion with values in environmental samples 
required to be within ±20 – 50 % those determined by spiked standards [47]. For five compounds only 
one transition was possible due to low response in the mass spectrometer, including fluoxetine, 
norfluoxetine, nortramadol, norpropoxyphene and 1,7-dimethylxanthine. As only one transition does 
not achieve four identification points, analysis of these compounds will be on a semi-quantitative basis. 
The ion ratios of MRM transitions in surface water spiked before extraction are provided in Table S2. 
3.3 Solid-phase extraction 
One of the greatest challenges with multi-residue analysis is the selection of sorbent able to give 
acceptable recoveries for all compounds characterised by different physicochemical properties. In this 
work, several different sorbents were investigated, amongst them were polymer and silica-based 
sorbents capable of non-polar and/or ion-exchange interactions (see section 2.3), with the aim of 
achieving one extraction step for all compounds. Of the sorbents investigated, the Oasis HLB and Oasis 
MCX were found to give the highest recoveries for the majority of compounds. The HLB gave superior 
recoveries most notably for heroin and the antidepressants, whereas the MCX provided improved 
recoveries for ecgonidine. An advantage of the MCX is the need to ionise basic compounds which 
requires an acidic pH (~pH 2.0) for extraction, a pH that promotes the stability of many compounds 
studied in this work [21], compared to an optimum neutral pH for the HLB sorbent. Additionally, as 
basic compounds are retained by the MCX through mixed mode interactions, an organic solvent 
washing step may be incorporated to remove acidic and neutral compounds, hence providing visibly 
cleaner extracts in comparison to the HLB. For these reasons, the Oasis MCX sorbent was selected.  
Besides SPE sorbent, several other factors were also investigated. The evaporation step was 
investigated (temperatures 30, 35, 40, 45, 50 °C) with an evaporation temperature of 40 °C providing 
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an optimal compromise between analyte recovery and time taken to evaporate SPE extract to dryness. 
Recovery of some compounds during the evaporation step was also shown to increase with the use of 
silanised vials, which prevent the adsorption of basic compounds onto –OH sites present on the surface 
of glassware. Sample volume was investigated in order to select the optimum volume to achieve the 
highest possible recoveries and limits of detection, while also being mindful that an increase in sample 
volume brings with it difficulties in terms of an increased time for extraction, possible matrix effects 
and difficulties in the collection, handling and storage of samples. Sample volumes selected for 
wastewater influent, effluent and river water were 100, 100 and 500 mL respectively. Two wash steps 
were employed to remove matrix and provide cleaner extracts, firstly acidified water followed by 
acidified organic solvent. The acidified water did not result in the loss of any compounds, however 
acidified methanol resulted in the breakthrough of temazepam, caffeine and 1,7-dimethylxanthine and 
subsequently lower recoveries of these compounds. Due to the significantly cleaner extracts provided 
with the washing step it was concluded that the washing step should remain. An elution volume of 2 
mL was shown to elute nearly 100 % of all compounds, thus to err on the side of caution an elution 
volume of 3 mL was selected. Prior to UPLC-MS/MS injection, samples must be filtered through a 
0.2µm filter to ensure the removal of particles which could potentially block the column pre-filter, thus 
several filter membranes were investigated (see section 2.3). PTFE membrane (Whatman) was selected 
as it provided recoveries of over 90 % for all compounds, apart from nordiazepam (88 %) and 
nitrazepam (83 %). 
High recoveries were obtained for the majority of compounds studied in UHQ water, river water, and 
WWTP influent and effluent. The variety of structured compounds with different physicochemical 
properties resulted in different recoveries, which for the majority of compounds were > 60 % in WWTP 
influent. Recovery values obtained for heroin and its deuterated analogue were unacceptably low and 
did not permit quantification. However, in addition to the three compounds lost during the wash step 
(caffeine, 1,7-dimethylxanthine and temazepam), results for heroin may be deemed ‘semi-quantitative’ 
due to internal standards able to compensate for the loss of compounds during the extraction procedure. 
EDDP and EMDP showed highly variable recoveries across the different matrices studied. 
Deuterated internal standards were added prior to SPE extraction in order to compensate for losses or 
enhancement of compounds during both the sample preparation procedure and resulting from matrix 
effects. Absolute and relative (relative to deuterated internal standard) recoveries are presented in Table 
2.  
3.4 Quantification and method validation parameters 
Concentrations of compounds were calculated using the standard calibration curve for the surface 
water spiked with compounds before extraction, which were constructed using a detector response 
defined as the ratio of the peak ion (the specific product ion of the highest intensity) to the base peak 
ion of the internal standard. 
The mean correlation coefficients (R
2
) of the calibration curves prepared in sample diluent were 
typically higher than 0.997 and showed good linearity in the range 0 – 1000 µg L-1. Similarly the R2 
values of the calibration curves prepared in surface water spiked before extraction were typically higher 
than 0.997 and showed good linearity in the range 0 – 1000 ng L-1 for the majority of compounds 
(Table 1). An exception to this was creatinine, with an unacceptable R
2
 value (0.929) when spiked in 
surface water before extraction. This value is likely to be a result of poor SPE recovery at higher 
concentrations as an excellent R
2
 value was obtained in spiked sample diluent. As high concentrations 
of creatinine are found is wastewater, direct injection of samples could be conducted to analyse 
creatinine. 
The instrumental and method limits of detection and quantification are presented in Table 1. Method 
limits of quantification were in general similar or in some cases lower than those reported by previous 
authors, leading to advancement on current methods due to the number of compounds incorporated into 
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this multi-residue method. The instrumental limits of quantification varied from 0.1 µg L
-1
 for several 
compounds including cocaine, benzoylecgonine and EDDP to 10 µg L
-1
 for creatinine. The method 
limits of detection were at low nanogram per litre levels and ranged from 0.1 ng L
-1
 for compounds 
including cocaine, benzoylecgonine, norbenzoylecgonine and 2-oxo-3-hydroxy-LSD to 100 ng L
-1
 for 
caffeine. Method quantification limits ranged from 0.6 to 154.2 ng L
-1
 in effluent and from 0.5 to 139.9 
ng L
-1
 in influent. 
The instrumental intra-day and inter-day repeatabilities, as indicated by standard deviation, were 
below 7 % and 8 %, respectively for nearly all samples (Table S3). The method intra-day repeatability 
was less than 8 % for nearly all samples, with inter-day repeatability’s in general less than 10 % (Table 
S4). The method accuracy range was within -33.1 to 30.1 % (Table S5).  
3.5 Environmental application  
The new multi-reside method was used to analyse stimulants, opiod and morphine derivatives, 
benzodiazepines, antidepressants, dissociative anesthetics, drug precursors and human urine indicators 
in wastewater and river water in the UK environment.  
Wastewater grab samples, both influent and effluent, were collected from seven WWTPs in the UK 
in June 2010 during a period of low rainfall.  Three of the wastewater plants sampled served small rural 
communities (population 10,000 - 15,000), with the remaining four plants serving large urban 
populations (population 200,000 – 308,000). River water was sampled along a major river in the UK at 
six locations near to discharge points of the sampled WWTPs. Maximum and average concentration 
values of all three matrices are shown in Table 3. 
Of the targeted 65 compounds, 47 compounds were detected at levels above the MQL in WWTP 
influent, 46 in WWTP effluent and 38 compounds in river water. Unusually high concentrations of 
amphetamine in relation to other monitoring campaigns by other authors were detected in two of the 
seven WWTP influent samples (1583 and 2300 ng L
-1
). Similarly, concentrations of tramadol and its 
metabolite nortramadol were found to be unusually high in all three studied matrices. Many of the 
compounds present in wastewater influent are not effectively removed by the treatment systems and 
compounds are consequently discharged into the rivers.  
4. CONCLUSIONS 
A new-multi residue method was developed for the environmental monitoring of 65 stimulants, opiod 
and morphine derivatives, benzodiazepines, antidepressants, dissociative anaesthetics, drug precursors 
and human urine indicators. The methodology enabled all compounds to be analysed through the usage 
of one extraction step, one reconstitution step and one LC-MS/MS method, thus overcoming many 
limitations of previously published work in which extra steps were required or a relatively small 
number of compounds were analysed. The method employed solid phase extraction with the usage of a 
strong cation-exchange mixed-mode polymeric sorbent (Oasis MCX, 60 mg) and subsequent ultra 
performance liquid chromatography positive electrospray ionisation tandem mass spectrometry. The 
usage of a 1.7 µm particle size column, 1 mm in diameter and 150 mm in length led to the use of very 
low flow rates (0.04 mL min
-1
), and as a consequence gave good sensitivity, low mobile phase 
consumption and short retention times for all compounds (from 2.9 to 23.1 min). 
This work, for the first time to the authors’ knowledge, has developed an analytical method to 
measure crack cocaine metabolites, anhydroecgonine methyl ester and ecgonidine, in the aqueous 
environment. Thereby potentially measuring the trends of crack cocaine use and differentiating the use 
of powder cocaine to that of crack cocaine. Although these crack cocaine tracers were not detected in 
this work, it should be noted that the number of environmental samples was relatively small. It may 
also be the case that these compounds are present at concentrations lower than the method detection 
limit, hence may be the subject of further analytical development. Additionally, this paper describes the 
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potential to monitor drug manufacturing precursors in order to indicate the manufacture of illicit drugs 
in a local area.  
The method was sensitive enough to detect many compounds in the aqueous environment, providing 
high SPE recoveries for nearly all compounds and limits of quantification in the low nano gram per litre 
range. The developed method was applied to wastewater (influent and effluent) and river water in the 
UK. The results confirmed that the multi-residue method is suitable, with the detection of many 
compounds in all matrices studied. Many drugs of abuse were found not only in WWTP influent, but 
also WWTP effluent and at lower levels in UK river water.  
The developed methodology presented will be employed within the UK to monitor wastewater at 
various geographical locations throughout the year in order to provide information on drug 
consumption and drug trends. Effluent from WWTPs with various different treatment systems will be 
monitored to assess the removal efficiency of the studied compounds. Additionally, river water will be 
monitored in order to assess the impact of the discharge from WWTPs into receiving waters. 
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Table 1 – Performance data for studied compounds in sample diluent, surface water, wastewater effluent and wastewater influent  
Compound tR
d  Sample diluenta  Surface waterb  WWTP effluentb  WWTP influentb 
 (min)  Linearity range  R2,   IDLS/N IQLS/N  Linearity range  R
2,   MDLS/N MQLS/N  MDLcalc
c MQLcalc
c  MDLcalc
c MQLcalc
c 
      (µg L-1)       (µg L-1) (µg L-1)   (ng L-1)       (ng L-1) (ng L-1)   (ng L-1) (ng L-1)   (ng L-1) (ng L-1) 
Stimulants and their metabolites                          
Cocaine 11.8  0.025 - 1000  0.999  0.025 0.10  0.05 - 750  0.999  0.05 0.10  0.2 0.6  0.2 0.7 
Benzoylecgonine 10.7  0.025 - 1000  0.999  0.025 0.10  0.05 - 500  0.992  0.05 0.10  0.2 0.6  0.2 0.7 
Norbenzoylecgonine 11.4  0.025 - 750  0.998  0.025 0.10  0.05 - 500  0.996  0.05 0.10  0.2 0.8  0.2 0.8 
Norcocaine 12.8  0.025 - 1000  0.999  0.025 0.10  0.05 - 1000  0.998  0.05 0.10  0.2 0.7  0.2 0.8 
Cocaethylene 13.9  0.025 - 750  0.999  0.025 0.10  0.05 - 750  0.998  0.05 0.10  0.1 0.6  0.2 0.9 
Anhydroecgonine methyl ester 3.6  0.100 - 750  0.995  0.100 0.50  0.50 - 750  0.995  0.50 5.00  2.5 12.3  2.8 14.2 
Ecgonidine  3.0  0.100 - 750  0.997  0.100 0.50  1.00 - 750  0.994  1.00 5.00  6.3 31.5  3.0 15.2 
Amphetamine   7.5  0.100 - 1000  0.999  0.100 0.50  0.50 - 1000  0.999  0.50 1.00  0.4 2.1  1.0 5.1 
Methamphetamine  7.9  0.025 - 1000  0.999  0.025 0.10  0.05 - 1000  0.999  0.05 0.10  0.1 0.6  0.1 0.6 
Methcathinone 5.6  0.075 - 1000  0.999  0.075 0.50  0.10 - 1000  0.992  0.10 1.00  0.8 5.4  1.5 9.7 
Benzylpiperazine (BZP) 4.3  0.500 - 1000  0.998  0.500 1.00  1.00 - 750  0.994  1.00 5.00  4.2 8.3  4.8 9.6 
Trifluoromethylphenylpiperazine (TFMPP) 14.5  0.025 - 1000  0.999  0.025 0.10  0.05 - 500  0.998  0.05 0.10  0.3 1.3  0.2 0.7 
                          
Hallucinogens and their metabolites                          
MDA  8.1  0.050 - 1000  0.999  0.050 0.50  0.10 - 1000  0.999  0.10 0.50  0.4 4.2  0.4 4.2 
MDMA (Ecstasy) 8.3  0.025 - 1000  1.000  0.025 0.10  0.10 - 1000  0.998  0.10 0.50  0.2 0.8  0.2 0.7 
MDEA (MDE) 9.4  0.025 - 1000  1.000  0.025 0.10  0.05 - 1000  0.999  0.05 0.10  0.5 1.8  0.3 1.1 
MBDB 10.3  0.025 - 1000  0.998  0.025 0.10  0.05 - 1000  1.000  0.05 0.10  0.3 1.2  0.2 0.7 
BDB 10.3  0.075 - 100  0.993  0.075 0.50  0.50 - 100  0.995  0.50 1.00  0.5 3.4  0.3 2.0 
Mescaline 7.0  0.500 - 1000  0.999  0.500 1.00  1.00 - 1000  0.997  1.00 5.00  22.8 45.6  26.5 52.9 
LSD 13.8  0.025 - 1000  0.999  0.025 0.10  0.05 - 1000  0.998  0.05 0.10  0.2 0.7  0.2 0.7 
O-H-LSD 9.1  0.025 - 1000  0.999  0.025 0.10  0.05 - 250  0.999  0.05 0.10  0.2 0.7  0.2 0.9 
                          
Human indicators                          
Caffeine 9.0  0.100 - 1000  0.999  0.100 0.50  50.00 - 10000  0.991  50.00 100.00  19.2 96.2  23.8 119.0 
1,7-dimethylxanthine 6.1  0.100 - 1000  0.998  0.100 0.50  1.00 - 1000  0.939  1.00 5.00  9.6 48.1  16.7 83.3 
Nicotine 3.3  0.075 - 1000  0.992  0.075 0.50  1.00 - 1000  0.995  1.00 5.00  2.0 13.5  0.7 4.7 
Continine 3.6  0.075 - 750  0.999  0.075 1.00  0.50 - 250  0.991  0.50 5.00  4.0 53.9  2.6 34.0 
Creatinine 2.9  0.500 - 7500  0.996  0.500 10.00  - - -  -  - -  - -  - - 
                          
Opiods, morphine derivatives and their metabolites                         
Heroin 11.4  0.075 - 1000  0.999  0.075 0.50  5.00 - 1000  0.997  5.00 10.00  23.1 154.2  21.0 139.9 
6-acetylmorphine 6.4  0.075 - 1000  0.999  0.075 0.50  0.10 - 1000  1.000  0.10 0.50  0.3 2.1  0.4 2.6 
Codeine 4.8  0.075 - 1000  0.999  0.075 0.50  0.10 - 1000  0.999  0.10 0.50  0.5 3.2  0.6 3.7 
Norcodeine 5.1  0.100 - 1000  0.998  0.100 0.50  0.50 - 1000  0.998  0.50 1.00  0.6 3.0  0.7 3.4 
Oxycocodone 5.4  0.075 - 750  0.999  0.075 0.50  0.10 - 750  0.998  0.10 0.50  0.7 4.3  0.7 4.9 
Oxymorphone 3.6  0.075 - 750  0.998  0.075 0.50  0.10 - 750  0.997  0.10 0.50  1.7 11.1  1.6 10.5 
Morphine 3.5  0.100 - 1000  1.000  0.100 0.50  0.50 - 1000  0.995  0.50 1.00  2.5 12.5  13.0 64.8 
Normorphine 3.5  0.100 - 1000  0.998  0.100 0.50  1.00 - 1000  0.994  1.00 5.00  2.2 11.1  6.5 32.6 
Dihydrocodeine 4.6  0.075 - 1000  0.999  0.075 0.50  0.10 - 1000  0.999  0.10 0.50  0.5 3.6  0.8 5.1 
Buprenorphine 17.3  0.100 - 1000  0.999  0.100 0.50  0.50 - 1000  0.999  0.50 1.00  0.7 3.5  1.8 8.9 
Norbuprenorphine 15.2  0.100 - 500  0.998  0.100 0.50  0.50 - 500  0.998  0.50 1.00  0.7 3.6  1.0 5.1 
Methadone 20.2  0.025 - 750  1.000  0.025 0.10  0.08 - 750  0.998  0.08 0.50  0.2 0.7  0.2 0.8 
EDDP 16.7  0.025 - 1000  0.999  0.025 0.10  0.10 - 1000  0.998  0.10 0.50  0.2 0.7  0.5 2.0 
EMDP 20.8  0.025 - 500  0.999  0.025 0.10  0.10 - 500  0.999  0.10 0.50  0.2 0.8  0.2 1.0 
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Fentanyl 15.3  0.025 - 750  0.997  0.025 0.10  0.08 - 750  0.994  0.08 0.50  0.1 0.6  0.2 0.8 
Norfentanyl 11.0  0.025 - 750  0.998  0.025 0.10  0.10 - 750  0.992  0.10 0.50  0.2 0.8  0.3 1.2 
Propoxyphene  19.6  0.075 - 1000  0.999  0.075 1.00  0.10 - 1000  0.998  0.10 5.00  0.3 4.5  0.4 5.2 
Norpropoxyphene 20.1  1.000 - 1000  0.997  1.000 5.00  1.00 - 1000  0.992  1.00 5.00  4.1 20.4  4.2 21.2 
Tramadol 11.4  0.050 - 1000  0.995  0.050 0.50  0.10 - 1000  0.995  0.10 1.00  0.3 2.8  0.5 5.1 
Nortramadol 12.5  1.000 - 500  0.998  1.000 5.00  1.00 - 500  0.993  1.00 5.00  2.4 12.0  1.5 7.4 
                          
Benzodiazpines and their metabolites                          
Temazepam 22.2  0.025 - 750  0.998  0.025 0.10  0.50 - 750  0.996  0.50 1.00  5.2 20.9  4.2 16.6 
Diazepam  23.1  0.075 - 1000  0.999  0.075 0.50  0.10 - 1000  0.997  0.10 0.50  0.5 3.3  0.9 6.0 
Nordiazepam  22.8  0.075 - 1000  0.997  0.075 0.50  0.10 - 1000  0.999  0.10 0.50  0.4 2.8  0.7 4.9 
Nitrazepam 19.8  0.075 - 500  0.995  0.075 0.50  0.10 - 500  0.999  0.10 1.00  0.5 3.3  0.5 3.2 
7-aminonitrazepam 6.2  0.075 - 500  0.996  0.075 0.50  0.50 - 500  0.997  0.50 1.00  1.2 7.9  1.9 12.9 
Oxazepam 21.7  0.075 - 1000  0.999  0.075 0.50  0.10 - 1000  0.998  0.10 0.50  0.9 5.7  0.9 5.9 
Chlordiazepoxide 17.2  0.075 - 1000  0.997  0.075 0.50  0.10 - 1000  0.999  0.10 0.50  0.5 3.0  0.5 3.1 
                          
Antidepressants and their metabolites                          
Dosulepin 19.2  0.075 - 1000  0.999  0.075 0.50  0.10 - 500  0.991  0.10 0.50  0.6 4.1  0.7 4.5 
Amitriptyline 20.8  0.075 - 1000  0.999  0.075 0.50  0.10 - 500  0.993  0.10 0.50  0.5 3.4  0.7 4.8 
Nortriptyline 21.3  0.075 - 1000  0.999  0.075 0.50  0.10 - 500  0.994  0.10 0.50  0.6 4.0  0.7 4.9 
Fluoxetine 21.6  0.075 - 1000  0.999  0.075 0.50  1.00 - 1000  0.998  1.00 5.00  0.5 3.3  0.5 3.0 
Norfluoxetine 21.8  0.075 - 250  0.996  0.075 0.50  0.50 - 250  0.999  0.50 5.00  0.5 3.4  0.4 2.7 
Venlafaxine 15.4  0.075 - 1000  0.999  0.075 0.50  0.10 - 250  0.992  0.10 0.50  0.5 3.6  0.5 3.5 
                          
Dissociative anesthetics and their 
metabolites 
                         
Phencyclidine  14.7  0.025 - 1000  0.999  0.025 0.10  0.08 - 1000  0.999  0.08 0.50  0.1 0.6  0.1 0.5 
Ketamine  10.4  0.025 - 1000  0.999  0.025 0.10  0.08 - 1000  0.999  0.08 0.50  0.3 1.3  0.3 1.0 
Norketamine  10.2  0.075 - 1000  0.999  0.075 0.50  0.10 - 1000  1.000  0.10 0.50  1.0 6.5  0.7 5.0 
                          
Other                          
Methaqualone 20.2  0.075 - 50  0.995  0.075 0.50  0.10 - 50  0.999  0.10 0.50  0.4 2.9  0.5 3.1 
Sildenafil (viagra) 18.8  0.500 - 250  0.997  0.500 1.00  1.00 - 250  0.998  1.00 5.00  2.3 4.7  2.3 4.6 
                          
Drug precursors                          
Ephedrine/Pseudoephedrine  5.9  0.500 - 1000  0.999  0.500 1.00  5.00 - 1000  0.995  5.00 10.00  2.6 5.2  2.8 5.6 
Norepehedrine 5.2   1.000 - 500   0.995   1.000 5.00   5.00 - 500   0.992   5.00 10.00   1.7 8.4   1.9 9.5 
a Sample diluent spiked with compounds 
b Surface water and wastewater spiked with compounds before extraction 
c MDLcalc and MQLcalc calculated for the lowest recorded SPE recovery 
d Retention time determined in wastewater influent spiked before extraction 
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Table 2 – SPE recovery for studied compounds 
Compound SPE recovery (%) (n=6)                                             
 WWTP influent
b
  WWTP effluent
b
  Surface water
d
  UHQ water
e
 
  Absolute Relative
a
     Absolute Relative
a
   Absolute Relative
a
   Absolute Relative
a
 
Stimulants and their metabolites                            
Cocaine 91 ± 2 96 ± 6  93 ± 4 102 ± 6  89 ± 3 102 ± 2  86 ± 7 103 ± 4 
Benzoylecgonine 103 ± 19 106 ± 20  91 ± 4 100 ± 2  91 ± 3 102 ± 1  88 ± 2 101 ± 3 
Norbenzoylecgonine 93 ± 4 96 ± 5  92 ± 3 101 ± 2  95 ± 3 106 ± 4  77 ± 2 89 ± 3 
Norcocaine 88 ± 5 92 ± 9  87 ± 2 95 ± 5  95 ± 6 109 ± 5  83 ± 9 100 ± 5 
Cocaethylene 88 ± 2 94 ± 5  95 ± 5 99 ± 5  95 ± 3 101 ± 2  88 ± 6 101 ± 3 
Anhydroecgonine methyl ester 74 ± 7 77 ± 10  92 ± 16 100 ± 16  74 ± 3 85 ± 3  92 ± 7 111 ± 15 
Ecgonidine  77 ± 5 79 ± 5  93 ± 80 101 ± 82  42 ± 7 47 ± 8  115 ± 32 131 ± 28 
Amphetamine   70 ± 17 78 ± 16  82 ± 13 95 ± 11  82 ± 4 99 ± 5  98 ± 29 100 ± 18 
Methamphetamine  76 ± 2 90 ± 3  81 ± 2 94 ± 3  81 ± 4 92 ± 3  84 ± 6 97 ± 1 
Methcathinone 33 ± 3 39 ± 3  56 ± 0 65 ± 3  62 ± 1 71 ± 4  64 ± 7 74 ± 12 
Benzylpiperazine (BZP) 101 ± 18 130 ± 29  84 ± 7 101 ± 9  76 ± 12 99 ± 22  52 ± 10 68 ± 17 
Trifluoromethylphenylpiperazine (TFMPP) 79 ± 9 102 ± 16  77 ± 11 92 ± 6  79 ± 10 101 ± 14  63 ± 5 81 ± 7 
                            
Hallucinogens and their metabolites                            
MDA  90 ± 3 97 ± 8  81 ± 4 105 ± 7  87 ± 10 99 ± 7  89 ± 4 102 ± 9 
MDMA (Ecstasy) 86 ± 3 94 ± 6  84 ± 6 102 ± 10  85 ± 4 104 ± 6  91 ± 4 103 ± 6 
MDEA (MDE) 86 ± 6 94 ± 7  89 ± 7 101 ± 10  87 ± 5 102 ± 3  88 ± 1 103 ± 2 
MBDB 88 ± 5 95 ± 8  85 ± 2 101 ± 4  85 ± 2 101 ± 4  88 ± 3 104 ± 4 
BDB 89 ± 5 96 ± 7  87 ± 3 103 ± 7  86 ± 3 102 ± 5  89 ± 2 104 ± 1 
Mescaline 85 ± 18 89 ± 15  103 ± 22 108 ± 10  89 ± 3 96 ± 3  86 ± 3 103 ± 2 
LSD 80 ± 2 97 ± 8  99 ± 23 106 ± 7  51 ± 8 101 ± 6  66 ± 10 103 ± 3 
O-H-LSD 78 ± 5 95 ± 13  84 ± 4 91 ± 17  76 ± 5 153 ± 38  68 ± 1 108 ± 11 
                            
Human indicators                            
Caffeine 36 ± 17 166 ± 120  7 ± 3 100 ± 28  10 ± 4 179 ± 82  18 ± 3 113 ± 5 
1,7-dimethylxanthine 15 ± 26 48 ± 113  3 ± 3 44 ± 42  6 ± 1 95 ± 20  55 ± 1 348 ± 50 
Nicotine 76 ± 9 90 ± 11  82 ± 31 84 ± 28  95 ± 36 104 ± 16  68 ± 4 110 ± 5 
Continine 37 ± 2 105 ± 6  48 ± 8 70 ± 12  53 ± 4 125 ± 22  105 ± 12 179 ± 23 
                            
Opiods, morphine derivatives and their metabolites                           
Heroin 3 ± 0 124 ± 6  2 ± 0 130 ± 18  1 ± 0 129 ± 25  1 ± 0 141 ± 26 
6-acetylmorphine 139 ± 16 141 ± 20  119 ± 5 129 ± 2  102 ± 7 113 ± 7  120 ± 8 130 ± 5 
Codeine 103 ± 4 105 ± 8  98 ± 10 106 ± 9  92 ± 2 103 ± 5  96 ± 7 104 ± 3 
Norcodeine 91 ± 3 92 ± 6  91 ± 5 98 ± 3  84 ± 2 94 ± 1  92 ± 12 100 ± 6 
Oxycocodone 57 ± 3 97 ± 9  75 ± 11 108 ± 10  82 ± 20 120 ± 24  62 ± 16 101 ± 4 
Oxymorphone 68 ± 6 115 ± 19  80 ± 6 117 ± 4  69 ± 9 102 ± 13  71 ± 23 114 ± 9 
Morphine 75 ± 6 85 ± 8  90 ± 2 99 ± 2  96 ± 5 153 ± 9  124 ± 4 120 ± 21 
Normorphine 92 ± 6 105 ± 8  103 ± 17 114 ± 17  68 ± 6 109 ± 15  96 ± 18 91 ± 5 
Dihydrocodeine 96 ± 7 93 ± 3  98 ± 7 99 ± 2  88 ± 1 102 ± 2  94 ± 8 98 ± 2 
Buprenorphine 77 ± 5 86 ± 6  93 ± 3 99 ± 3  84 ± 4 97 ± 2  80 ± 19 100 ± 3 
Norbuprenorphine 85 ± 4 96 ± 6  93 ± 3 100 ± 5  74 ± 2 86 ± 4  86 ± 13 109 ± 9 
Methadone 97 ± 6 99 ± 5  90 ± 2 102 ± 4  89 ± 4 106 ± 4  79 ± 25 97 ± 7 
EDDP 38 ± 4 107 ± 3  83 ± 13 120 ± 20  38 ± 5 88 ± 3  54 ± 4 92 ± 4 
EMDP 55 ± 3 57 ± 4  66 ± 3 75 ± 3  36 ± 3 43 ± 4  6 ± 2 7 ± 1 
Fentanyl 96 ± 7 98 ± 7  95 ± 5 100 ± 6  87 ± 1 102 ± 5  86 ± 13 102 ± 0 
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Norfentanyl 85 ± 2 86 ± 3  86 ± 5 91 ± 4  74 ± 7 87 ± 5  80 ± 6 96 ± 19 
Propoxyphene  90 ± 4 96 ± 7  87 ± 7 97 ± 6  106 ± 2 108 ± 4  79 ± 24 93 ± 10 
Norpropoxyphene 99 ± 9 93 ± 8  100 ± 4 111 ± 21  94 ± 4 112 ± 13  117 ± 41 165 ± 39 
Tramadol 96 ± 7 98 ± 13  105 ± 21 113 ± 19  91 ± 7 101 ± 5  87 ± 8 96 ± 16 
Nortramadol 101 ± 13 102 ± 11  78 ± 20 84 ± 22  80 ± 15 89 ± 15  104 ± 14 114 ± 21 
                            
Benzodiazpines and their metabolites                            
Temazepam 15 ± 8 80 ± 41  10 ± 5 48 ± 27  21 ± 2 100 ± 6  46 ± 24 98 ± 5 
Diazepam  105 ± 13 103 ± 10  90 ± 4 99 ± 3  89 ± 2 100 ± 2  80 ± 1 101 ± 2 
Nordiazepam  71 ± 4 70 ± 3  110 ± 4 122 ± 7  93 ± 7 105 ± 11  67 ± 14 84 ± 17 
Nitrazepam 92 ± 3 91 ± 4  95 ± 5 105 ± 7  79 ± 14 89 ± 19  44 ± 19 55 ± 23 
7-aminonitrazepam 36 ± 8 104 ± 30  44 ± 6 64 ± 10  50 ± 5 116 ± 20  21 ± 2 36 ± 6 
Oxazepam 54 ± 5 99 ± 7  51 ± 3 96 ± 4  62 ± 2 205 ± 5  66 ± 16 107 ± 5 
Chlordiazepoxide 86 ± 4 85 ± 5  93 ± 3 102 ± 5  90 ± 6 101 ± 9  75 ± 8 95 ± 8 
                            
Antidepressants and their metabolites                            
Dosulepin 67 ± 3 190 ± 14  76 ± 4 110 ± 5  79 ± 0 185 ± 23  56 ± 14 94 ± 18 
Amitriptyline 80 ± 6 226 ± 4  86 ± 2 124 ± 6  86 ± 12 204 ± 52  66 ± 23 111 ± 33 
Nortriptyline 64 ± 8 181 ± 7  76 ± 9 109 ± 12  55 ± 7 131 ± 32  64 ± 20 107 ± 27 
Fluoxetine 61 ± 4 88 ± 12  74 ± 5 104 ± 14  53 ± 17 101 ± 11  80 ± 66 99 ± 1 
Norfluoxetine 62 ± 9 89 ± 5  60 ± 11 83 ± 10  47 ± 21 87 ± 9  71 ± 60 87 ± 3 
Venlafaxine 91 ± 15 92 ± 15  85 ± 8 90 ± 6  97 ± 8 113 ± 7  91 ± 11 108 ± 6 
                            
Dissociative anesthetics and their 
metabolites 
                           
Phencyclidine  80 ± 2 103 ± 7  85 ± 0 103 ± 8  86 ± 2 110 ± 8  81 ± 6 103 ± 2 
Ketamine  70 ± 5 90 ± 6  84 ± 2 97 ± 4  90 ± 2 100 ± 5  92 ± 2 99 ± 4 
Norketamine  67 ± 7 86 ± 13  86 ± 3 99 ± 5  83 ± 3 91 ± 5  77 ± 7 82 ± 7 
                            
Other                            
Methaqualone 98 ± 5 97 ± 4  96 ± 10 103 ± 15  105 ± 4 101 ± 8  74 ± 4 95 ± 6 
Sildenafil (viagra) 81 ± 23 98 ± 26  97 ± 4 106 ± 16  87 ± 19 170 ± 16  61 ± 29 92 ± 34 
                            
Drug precursors                            
Ephedrine/Pseudoephedrine  73 ± 13 82 ± 11  85 ± 12 99 ± 12  102 ± 12 123 ± 27  99 ± 2 103 ± 9 
Norepehedrine 95 ± 3 108 ± 10  90 ± 11 104 ± 10  98 ± 16 116 ± 7  110 ± 27 112 ± 17 
                            
Internal standards                            
Cocaine-D3 96 ± 4     91 ± 3     87 ± 2     84 ± 5    
Benzoylecgonine-D8 97 ± 1     91 ± 4     89 ± 2     87 ± 4    
Cocaethylene-D8 94 ± 7     96 ± 4     94 ± 5     87 ± 3    
Amphetamine-D11 89 ± 5     86 ± 3     84 ± 9     97 ± 10    
Methamphetamine-D14 85 ± 4     86 ± 5     88 ± 6     87 ± 5    
MDA-D5 93 ± 5     77 ± 2     88 ± 6     88 ± 4    
MDMA-D5 92 ± 2     82 ± 3     82 ± 6     89 ± 3    
MBDB-D5 93 ± 3     84 ± 6     84 ± 2     85 ± 1    
MDEA-D5 92 ± 3     89 ± 2     86 ± 6     85 ± 3    
Caffeine-D9 24 ± 5     7 ± 0     6 ± 1     16 ± 3    
Nicotine-D4 85 ± 1     97 ± 13     96 ± 50     62 ± 3    
LSD-D3 83 ± 7     94 ± 17     51 ± 11     64 ± 7    
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Heroin-D9 2 ± 0     2 ± 0     1 ± 0     1 ± 0    
Oxycodone-D6 59 ± 5     69 ± 4     68 ± 4     61 ± 18    
Morphine-D6 89 ± 1     91 ± 1     63 ± 4     106 ± 20    
Methadone-D9 98 ± 3     88 ± 2     84 ± 0     80 ± 19    
EDDP-D3 35 ± 3     69 ± 1     43 ± 5     59 ± 5    
Fentanyl-D5 98 ± 1     94 ± 4     86 ± 4     84 ± 13    
Codeine-D6 99 ± 6     93 ± 2     90 ± 2     92 ± 7    
Dihydrocodeine-D6 103 ± 7     99 ± 7     86 ± 3     95 ± 10    
Buprenorphine-D4 89 ± 1     94 ± 3     86 ± 2     80 ± 19    
Propoxyphene-D11 95 ± 3     90 ± 4     98 ± 2     83 ± 18    
Norpropoxyphene-D5 107 ± 11     93 ± 17     85 ± 7     70 ± 12    
Temazepam-D5 18 ± 2     23 ± 2     21 ± 2     48 ± 26    
Diazepam-D5 102 ± 2     91 ± 3     89 ± 3     79 ± 2    
Oxazepam-D5 55 ± 2     53 ± 4     30 ± 1     63 ± 18    
Fluoxetine-D6 70 ± 8     71 ± 5     53 ± 19     81 ± 66    
PCP-D5 78 ± 3     83 ± 7     78 ± 6     79 ± 6    
Ketamine-D4 78 ± 3     87 ± 5     91 ± 6     93 ± 6    
Mescaline-D9 95 ± 6     96 ± 12     93 ± 3     83 ± 1    
Methaqualone-D7 101 ± 1         94 ± 5         104 ± 5         78 ± 4       
a Relative recovery to surrogate/internal standard  
c Average recovery from WWTP influent and effluent spiked before extraction (two replicates at three concentrations: 100, 500 and 1000 ng L-1) 
d Average recovery from surface water spiked before extraction (two replicates at three concentrations: 20, 100 and 200 ng L-1) 
e Average recovery from UHQ water spiked before extraction (two replicates at three concentrations: 100, 500 and 1000 ng L-1) 
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Table 3 – Concentration of compounds in influent, effluent and river water from 7 WWTPs and 6 river locations in the UK 
Compound WWTP influent (n=7)  WWTP effluent (n=7)  River water (n=6) 
  samples  
(>LOQ)
a
 
Conc. Max  
(ng L
-1
)
b
 
Conc. Mean 
 (ng L
-1
)
c
 
  Samples 
(>LOQ)
a
 
Conc. Max  
(ng L
-1
)
b
 
Conc. Mean 
 (ng L
-1
)
c
 
  Samples 
 (>LOQ)
a
 
Conc. Max  
(ng L
-1
)
b
 
Conc. Mean  
(ng L
-1
)
c
 
Stimulants and their metabolites            
Cocaine 7 109.0 70.9  6 65.2 29.2  6 14.0 6.0 
Benzoylecgonine 7 368.3 243.1  7 293.3 115.9  6 52.5 26.8 
Norbenzoylecgonine 7 15.2 7.5  7 12.0 7.0  5 2.8 1.8 
Norcocaine 1 1.0 1.0  0 <MDL <MDL  1 0.1 0.1 
Cocaethylene 7 5.4 3.0  4 5.4 3.8  5 1.4 0.6 
Anhydroecgonine methyl ester 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
Ecgonidine  0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
Amphetamine   7 2300.1 829.6  7 24.4 7.7  4 4.3 3.3 
Methamphetamine  6 3.8 2.0  3 1.2 1.0  0 <MDL <MDL 
Methcathinone 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
Benzylpiperazine (BZP) 4 37.6 24.5  7 66.3 30.9  5 65.3 26.0 
Trifluoromethylphenylpiperazine (TFMPP) 6 9.8 4.8  7 9.4 4.6  5 1.1 0.6 
            
Hallucinogens and their metabolites            
MDA  2 15.2 10.4  2 24.5 15.4  0 <MDL <MDL 
MDMA (Ecstasy) 7 137.9 39.0  7 155.7 37.5  5 24.8 8.7 
MDEA (MDE) 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
MBDB 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
BDB 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
Mescaline 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
LSD 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
O-H-LSD 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
            
Human indicators            
Caffeine 7 13759.1 9902.3  5 7137.0 2048.3  6 437.4 265.2 
1,7-dimethylxanthine 7 15285.8 9466.9  7 12456.1 3168.6  6 421.4 277.0 
Nicotine 7 7042.6 4446.0  6 89.9 52.1  6 56.4 32.3 
Continine 1 43.7 43.7  0 <MDL <MDL  0 <MDL <MDL 
            
Opiods, morphine derivatives and their 
metabolites 
           
Heroin 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
6-acetylmorphine 5 69.7 22.2  0 <MDL <MDL  0 <MDL <MDL 
Codeine 7 2703.5 2121.2  7 1206.2 436.9  6 341.7 128.2 
Norcodeine 7 150.9 111.7  5 64.6 32.8  5 19.9 8.9 
Oxycocodone 6 17.1 12.2  6 25.3 12.0  5 7.1 3.0 
Oxymorphone 3 23.5 19.9  0 <MDL <MDL  0 <MDL <MDL 
Morphine 7 819.2 481.2  4 243.8 130.7  1 35.8 35.8 
Normorphine 7 364.2 202.6  1 61.9 61.9  0 <MQL <MQL 
Dihydrocodeine 7 526.1 320.7  7 316.7 145.5  6 90.1 36.4 
Buprenorphine 2 34.4 33.2  2 24.2 13.9  0 <MDL <MDL 
Norbuprenorphine 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
Methadone 7 171.1 87.9  7 68.8 49.6  6 18.4 10.0 
EDDP 7 342.2 193.0  7 161.6 89.1  6 38.2 19.1 
EMDP 1 5.7 5.7  3 2.3 1.7  2 1.0 0.8 
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Fentanyl 3 2.2 1.7  0 <MDL <MDL  0 <MDL <MDL 
Norfentanyl 2 9.8 6.9  1 1.1 1.1  0 <MDL <MDL 
Propoxyphene  1 10.7 10.7  2 8.6 7.1  0 <MDL <MDL 
Norpropoxyphene 0 <MDL <MDL  7 142.7 91.3  5 38.2 22.9 
Tramadol 7 6278.1 2758.7  7 1536.7 1225.6  6 441.8 221.4 
Nortramadol 7 7192.8 2457.3  7 538.6 432.6  5 265.8 148.5 
            
Benzodiazpines and their metabolites            
Temazepam 7 278.3 167.0  7 251.1 135.3  5 52.9 27.8 
Diazepam  0 <MDL <MDL  2 6.2 5.1  3 1.1 0.8 
Nordiazepam  7 51.5 25.2  7 14.2 9.9  5 5.5 3.2 
Nitrazepam 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
7-aminonitrazepam 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
Oxazepam 7 113.8 49.5  7 82.8 57.9  5 17.4 11.4 
Chlordiazepoxide 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
            
Antidepressants and their metabolites            
Dosulepin 7 418.7 227.6  7 121.0 57.2  6 32.2 9.7 
Amitriptyline 7 1055.5 659.0  7 222.7 129.8  6 71.6 29.5 
Nortriptyline 6 184.5 114.1  7 53.8 32.9  6 19.0 6.8 
Fluoxetine 7 175.9 86.1  6 43.3 29.3  3 13.5 9.0 
Norfluoxetine 7 118.0 62.8  3 20.1 13.2  7 <MQL <MQL 
Venlafaxine 7 343.8 249.0  7 269.6 187.5  6 71.6 35.1 
            
Dissociative anesthetics and their metabolites            
Phencyclidine  0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
Ketamine  7 160.0 79.4  7 228.4 129.6  6 51.0 21.3 
Norketamine  6 96.4 26.5  7 54.3 28.0  5 14.4 5.8 
            
Other            
Methaqualone 0 <MDL <MDL  0 <MDL <MDL  0 <MDL <MDL 
Sildenafil (viagra) 7 49.8 24.9  5 10.2 7.0  0 <MDL <MDL 
            
Drug precursors            
Ephedrine/Pseudoephedrine  7 1032.1 685.2  2 126.9 70.2  3 16.5 11.7 
Norepehedrine 7 134.0 85.9   1 59.2 59.2   0 <MDL <MDL 
a Number of samples with concentration level >MQL 
b Maximum concentration measured 
c Average concentration measured in those samples with levels >MQL 
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Fig 1 - UPLC-MS/MS separations for compounds spiked into WWTP influent before extraction 
(concentration, 500 ng L
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Table S1 - Selected pharmaceuticals and their properties 
Compound CAS Formula MW Pka    LogP   Supplier 
        Experimental
a
 Calculated
b
   Experimental
a
 Calculated
b
     
Stimulants and their metabolites           
Cocaine 50-36-2 C17H21NO4 303.4 8.6 (20°) 8.9  2.3 2.3  LGC 
Benzoylecgonine 519-09-5 C16H19NO4 289.3  10.8, 3.3  −1.3 2.3  LGC 
Norbenzoylecgonine 60426-41-7 C15H17NO4 275.3  10.4, 3.4   2.6  LGC 
Norcocaine N/A C16H19NO4 289.3  9.0   3.1  LGC 
Cocaethylene 529-38-4 C18H23NO4 317.4  9.0   2.8  LGC 
Anhydroecgonine methyl ester 43021-26-7 C10H
15
NO2 181.2  8.0   0.4  LGC 
Ecgonidine  74242-55-0 C8H11NO2 153.2  9.6, 3.8   1.5  LGC 
Amphetamine   300-62-9             C9H13N 135.2 10.1 9.9  1.8 1.8  LGC 
Methamphetamine  R-(-):33817-09-3, S-(+):537-46-2                                                                           C10H15N 149.2 10.1 10.4  2.1 2.2  LGC 
Methcathinone 49656-78-2 C10H13NO 163.2  7.1   0.4  Sigma-Aldrich 
Benzylpiperazine (BZP) N/A C11H16N2 176.3  9.3, 3.4   1.1  LGC 
Trifluoromethylphenylpiperazine (TFMPP) N/A C11H13F3N2 230.2  8.8, 2.1   1.3  LGC 
           
Hallucinogens and their metabolites           
MDA  4764-17-4 C10H13NO2 179.2  9.9  1.64 1.6  LGC 
MDMA (Ecstasy) 4254210-9 C11H15NO2 193.2  (benzene, pH 9.0) 9.4 10.3   2.1  LGC 
MDEA (MDE) 82801-81-8 C12H17NO2 207.3  10.3   2.6  LGC 
MBDB 145225-00-9 C12H17NO2 207.3  10.5   2.6  LGC 
BDB N/A C11H15NO2 193.2  10   2.2  LGC 
Mescaline 832-92-8 C11H17NO3 211.3 9.6 9.6  0.8 0.5  LGC 
LSD 50-37-3 C20H25N3O 323.4 7.5 7.4    2.9 2.7  LGC 
O-H-LSD N/A C20H25N3O3 355.4  11.7, 6.8   -1.9  LGC 
           
Human indicators           
Caffeine 58-08-2 C8H10N4O2 194.2 14.0 (25°), 10.4 (40°) 0.5    −0.07 -0.6  Sigma-Aldrich 
1,7-dimethylxanthine 611-59-6 C7H8N4O2 180.2  8.5, 0.2    -0.9  Sigma-Aldrich 
Nicotine 54-11-5 C10H14N2 162.2 7.9, 3.2, (25°) 8.0, 3.2    1.2 0.6  Sigma-Aldrich 
Continine 486-56-6 C10H12N2O 176.2  4.7   0.07  Sigma-Aldrich 
Creatinine 60-27-5 C4H7N3O 113.1  6.9   -0.8  Fisher-Acros 
           
Opiods, morphine derivatives and their metabolites          
Heroin 561-27-3 C21H23NO5 369.4 7.6 (23°) 7.9  1.58 1.6  LGC 
6-acetylmorphine 2784-73-8 C19H21NO4 327.4  9.4, 8.0   1.6  LGC 
Codeine 76-57-3 C18H21NO3 299.4 8.2 (20°) 13.4, 8.2  0.6 1.4  Sigma-Aldrich 
Norcodeine 467-15-2 C17H19NO3 285.3 9.2 (25°) 13.3, 9.3  0.7 0.5  LGC 
Oxycocodone 76-42-6 C18H21NO4 315.4 8.9 (20°) 13.1, 7.6  0.7 1.6  LGC 
Oxymorphone 76-41-5 C17H19NO4 301.3 9.3, 8.5  13.5, 9.2, 7.6  0 1.2  LGC 
Morphine 57-27-2 C17H19NO3 285.3 9.9, 8.0 (20°) 13.5, 9.5, 8.3  –0.1 0.9  LGC 
Normorphine 466-97-7 C16H17NO3 271.3 9.8 (25°) 13.4, 9.5, 9.2  −2.8 0.0  LGC 
Dihydrocodeine 125-28-0 C18H23NO3 301.4 8.8 (25°) 8.4     0.6  LGC 
Buprenorphine 52485-79-7 C29H41NO4 467.6 8.5, 10.0 9.5, 8.3  5.0 2.8  LGC 
Norbuprenorphine 78715-23-8 C25H35NO4 413.6  9.8, 9.1   1.2  LGC 
Methadone 76-99-3 C21H27NO 309.4 8.94 (25°), 8.3 (20°) 9.1  3.9 3.9  Sigma-Aldrich 
EDDP 66729-78-0 C21H25N 291.4  8.4   5.0  LGC 
EMDP N/A C20H23N 277.4  8.1   5.8  LGC 
Fentanyl 437-38-7 C22H28N2O 336.5  8.9, 0.3  2.3 3.7  LGC 
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Norfentanyl N/A C14H20N2O 232.3  9.8, 0.3   1.7  LGC 
Propoxyphene  469-62-5 C22H29NO2 339.5 6.3 9.2  4.2 4.1  LGC 
Norpropoxyphene 159208-83-0 C21H27NO2 325.4  10.1   3.7  LGC 
Tramadol 36282-47-0 C16H25NO2 263.4 9.4, 8.3 9.6  3.0 2.3  Sigma-Aldrich 
Nortramadol N/A C15H23NO2 249.4  10.6   1.7  LGC 
           
Benzodiazpines and their metabolites           
Temazepam 846-50-4 C16H13ClN2O2 300.7 1.6 11.7, 1.6  2.2 2.2  LGC 
Diazepam 439-15-5 C16H13ClN2O 284.7 3.3 (20°) 3.4  2.7 2.8  LGC 
Nordiazepam  1088-11-5 C15H11ClN2O 270.7 12.0, 3.5  11.7, 3.2  2.9 2.8  LGC 
Nitrazepam 146-22-5 C15H11N3O3 281.3 10.8, 3.2 (20°) 11.4, 2.6  2.1 2.4  Sigma-Aldrich 
7-aminonitrazepam 4928-02-3 C15H13N3O 251.3  12.3, 4.3, 2.3   1.1  LGC 
Oxazepam 604-75-1 C15H11ClN2O2 286.7 11.6, 1.7 (20°) 12.8, 10.9, 1.2  2.2 2.2  LGC 
Chlordiazepoxide 58-25-3 C16H14ClN3O 299.8 4.8 8.6, 6.5  2.4 2.8  LGC 
           
Antidepressants and their metabolites           
Dosulepin 113-53-1 C19H21NS 295.4  9.1  2.8 4.3  LGC 
Amitriptyline 549-18-8 C20H23N 277.4 9.4 (25°) 9.2  5.0 4.4  Sigma-Aldrich 
Nortriptyline 894-71-3 C19H21N 263.4 9.7 10.0  1.7 4.0  Sigma-Aldrich 
Fluoxetine 59333-67-4 C17H18F3NO 309.3  10.1  1. 3.9  LGC 
Norfluoxetine N/A C16H16F3NO 295.3  9.1   3.8  LGC 
Venlafaxine 99300-78-4 C17H27NO2 277.4  9.3  0.4 2.5  Sigma-Aldrich 
           
Dissociative anesthetics and their metabolites           
Phencyclidine (PCP) 77-10-1 C17H25N 243.4 8.5 8.2  4.7 4.3  LGC 
Ketamine  1867-66-9 C13H16ClNO 237.7 7.5 6.5  3.1 3.0  Sigma-Aldrich 
Norketamine  N/A C12H14ClNO 223.7 6.7 6.3   2.4  LGC 
           
Other           
Methaqualone 72-44-6 C16H14N2O 250.3 2.5 3.0  4.3 2.5  LGC 
Sildenafil (viagra) 139755-83-23 C22H30N6O4S 474.6 8.7 6.0, 0.6   1.6  LGC 
           
Drug precursors           
Ephedrine 50-98-6 C10H15NO 165.2 9.6 (25°) 9.5  1.1 1.0  LGC 
Norepehedrine 154-41-6 C9H13NO 151.2  12.1, 8.5   0.4  Sigma-Aldrich 
Pseudoephedrine  345-78-8 C10H15NO 165.2 9.8 9.5   0.9 1.0   Sigma-Aldrich 
a Moffat, A.C.; Osselton, D. M.; Widdop, B. Clarke's analysis of drugs and poisons, pharmaceutical press 2004, http://www.medicinescomplete.com/mc/clarke/current/, accessed June 2009 
b ACD/I-lab accessed via ACD/chemsketch, version 12.0, Advanced chemistry development Inc. Toronto, ON, Canada. www.acdlabs.com 
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Table S2. Optimised MRM conditions and surrogate/internal standard used for quantification 
Compound CV/CE
a
 MRM1 (quantification) CV/CE
a
 MRM2 
(confirmation) 
MRM ratio
b
 ± % RSD Internal standard 
Stimulants and their metabolites         
Cocaine 40/20 304.2 > 182.1 40/31 304.2 > 82.1 2.56 ± 0.04 Cocaine-D3 
Benzoylecgonine 38/19 290.2 > 168.1 38/30 290.2 > 105.1 2.67 ± 0.04 Benzoylecgonine-D8 
Norbenzoylecgonine 32/16 276.1 > 154.0 32/21 276.1 > 136.1 1.53 ± 0.03 Benzoylecgonine-D8 
Norcocaine 40/15 290.2 > 168.1 40/24 290.1 > 136.1 1.76 ± 0.10 Cocaine-D3 
Cocaethylene 38/20 318.2 > 196.2 38/30 318.2 > 82.1 1.68 ± 0.03 Cocaethylene-D8 
Anhydroecgonine methyl ester 39/23 182.1 > 118.0 39/21 182.1 > 122.1 0.83 ± 0.09 Cocaine-D3 
Ecgonidine  37/23 168.1 > 91.1 37/20 168.1 > 122.1 2.68 ± 0.22 Benzoylecgonine-D8 
Amphetamine   18/8 136.2 > 119.1 18/16 136.2 > 91.1 4.55 ± 0.16 Amphetamine-D11 
Methamphetamine  24/19 150.2 > 91.1 24/10 150.2 > 119.1 2.82 ± 0.11 Methamphetamine-D14 
Methcathinone 28/19 164.1 > 131.0 28/12 164.1 > 146.1 0.55 ± 0.03 Methamphetamine-D14 
Benzylpiperazine (BZP) 35/20 177.1 > 91.1 35/15 177.1 > 85.1 6.18 ± 0.11 PCP-D5 
Trifluoromethylphenylpiperazine (TFMPP) 46/23 231.0 > 188.0 46/35 231.0 > 118.3 2.42 ± 0.06 PCP-D5 
         
Hallucinogens and their metabolites         
MDA  21/11 180.0 > 163.1 21/22 180.0 > 105.1 3.05 ± 0.07 MDA-D5 
MDMA (Ecstasy) 24/13 194.1 > 163.1 24/24 194.1 > 105.1 2.51 ± 0.08 MDMA-D5 
MDEA (MDE) 28/13 208.1 > 163.1 28/27 208.1 > 105.1 3.18 ± 0.05 MDEA-D5 
MBDB 26/20 208.1 > 135.1 26/11 208.1 > 177.1 2.52 ± 0.14 MBDB-D5 
BDB 20/9 194.1 > 177.1 20/16 194.1 > 135.1 4.03 ± 0.51 MBDB-D5 
Mescaline 46/12 212.3 > 195.1 46/18 212.3 > 180.1 1.83 ± 0.15 Mescaline-D9 
LSD 41/24 324.2 > 223.2 41/28 324.2 > 208.1 1.62 ± 0.04 LSD-D3 
O-H-LSD 41/24 356.2 > 237.1 41/24 356.2 > 74.1 1.46 ± 0.04 LSD-D3 
         
Human indicators         
Caffeine 38/15 195.1 > 138.0 38/23 195.1 > 110.0 2.93 ± 0.06 Caffeine-D9 
1,7-dimethylxanthine 54/21 181.0 > 124.1 none none -  - Caffeine-D9 
Nicotine 37/20 163.1 > 130.0 37/24 163.1 > 117.0 0.95 ± 0.04 Nicotine-D4 
Continine 34/21 177.1 > 80.0 34/22 177.1 > 98.1 3.15 ± 0.08 EDDP-D3 
Creatinine 31/11 114.0 > 86.1 31/16 114.0 > 72.1 2.54 ± 0.08 EDDP-D3 
         
Opiods, morphine derivatives and their 
metabolites 
        
Heroin 51/50 370.2 > 165.1 51/29 370.2 > 268.1 1.39 ± 0.04 Heroin-D9 
6-acetylmorphine 52/39 328.1 > 165.1 52/26 328.1 > 211.1 1.77 ± 0.04 Codeine-D6 
Codeine 49/57 300.2 > 152.1 49/25 300.2 > 215.1 1.22 ± 0.03 Codeine-D6 
Norcodeine 46/40 286.1 > 165.1 46/20 286.1 > 268.2 0.87 ± 0.03 Codeine-D6 
Oxycocodone 36/29 316.2 > 241.1 36/26 316.2 > 256.1 1.46 ± 0.04 Oxycodone-D6 
Oxymorphone 40/19 302.1 > 284.1 40/28 302.1 > 227.1 3.59 ± 0.09 Oxycodone-D6 
Morphine 53/56 286.1 > 152.1 53/38 286.1 > 165.1 1.33 ± 0.05 Morphine-D6 
Normorphine 45/49 272.1 > 152.1 45/43 272.1 > 165.0 1.34 ± 0.03 Morphine-D6 
Dihydrocodeine 53/33 302.1 > 199.1 53/60 302.1 > 128.1 1.48 ± 0.04 Dihydrocodeine-D6 
Buprenorphine 69/45 468.3 > 84.1 69/43 468.3 > 101.0 1.69 ± 0.04 Buprenorphine-D4 
Norbuprenorphine 60/47 414.3 > 83.0 60/39 414.3 > 101.1 1.26 ± 0.03 Buprenorphine-D4 
Methadone 31/15 310.2 > 265.1 31/28 310.2 > 105.1 2.26 ± 0.08 Methadone-D9 
EDDP 50/29 278.2 > 234.1 50/24 278.2 > 249.1 1.15 ± 0.11 EDDP-D3 
EMDP 47/21 264.2 > 235.1 47/31 264.2 > 220.2 1.04 ± 0.02 Methadone-D9 
Fentanyl 44/38 337.2 > 105.1 44/23 337.2 > 188.2 1.01 ± 0.03 Fentanyl-D5 
Norfentanyl 27/20 233.2 > 84.0 27/15 233.2 > 177.1 17.68 ± 0.44 Fentanyl-D5 
Propoxyphene  19/8 340.2 > 266.2 19/22 340.2 > 143.0 24.40 ± 1.28 Propoxyphene-D11 
Norpropoxyphene 15/7 326.2 > 252.1 none none -  - Norpropoxyphene-D5 
Tramadol 24/17 264.2 > 58.1 24/11 264.2 > 246.3 92.34 ± 3.07 Codeine-D6 
Nortramadol 21/8 250.2 > 232.1 none none - - - Codeine-D6 
         
Benzodiazpines and their metabolites         
Temazepam 37/21 301.1 > 255.1 37/14 301.1 > 283.1 1.97 ± 0.07 Temazepam-D5 
Diazepam  54/27 285.0 > 154.1 54/31 285.0 > 193.1 1.32 ± 0.02 Diazepam-D5 
Nordiazepam  51/29 271.1 > 140.1 51/29 271.1 > 165.0 1.26 ± 0.06 Diazepam-D5 
Nitrazepam 44/24 282.1 > 236.1 44/37 282.1 > 180.1 6.12 ± 0.29 Diazepam-D5 
7-aminonitrazepam 48/25 252.1 > 121.1 48/40 252.1 > 94.1 3.05 ± 0.09 EDDP-D3 
Oxazepam 38/21 287.1 > 241.1 38/15 287.1 > 269.0 1.15 ± 0.04 Oxazepam-D5 
Chlordiazepoxide 32/15 300.1 > 283.1 32/25 300.1 > 227.1 2.04 ± 0.08 Diazepam-D5 
         
Antidepressants and their metabolites         
Dosulepin 34/24 296.1 > 218.1 34/24 296.1 > 223.1 0.81 ± 0.02 EDDP-D3 
Amitriptyline 37/26 278.2 > 91.1 37/18 278.2 > 233.2 1.10 ± 0.02 EDDP-D3 
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Nortriptyline 33/16 264.2 > 233.1 33/23 264.2 > 91.0 1.30 ± 0.03 EDDP-D3 
Fluoxetine 25/8 310.3 > 148.1 none none -  - Fluoxetine-D6 
Norfluoxetine 17/7 296.2 > 134.1 none none -  - Fluoxetine-D6 
Venlafaxine 27/12 278.2 > 260.1 27/32 278.2 > 121.0 3.93 ± 0.11 Fentanyl-D5 
         
Dissociative anesthetics and their metabolites         
Phencyclidine  18/14 244.2 > 159.1 18/34 244.2 > 91.1 1.24 ± 0.03 PCP-D5 
Ketamine  31/27 238.1 > 125.0 31/15 238.1 > 220.1 2.71 ± 0.04 Ketamine-D4 
Norketamine  23/27 224.0 > 125.0 23/12 224.0 > 207.1 1.02 ± 0.03 Ketamine-D4 
         
Other         
Methaqualone 58/27 251.1 > 132.1 58/42 251.1 > 91.1 5.53 ± 0.59 Methaqualone-D7 
Sildenafil (viagra) 60/28 475.3 > 100.2 60/40 475.3 > 283.2 4.46 ± 0.07 PCP-D5 
         
Drug precursors         
Ephedrine/Pseudoephedrine  23/12 166.1 > 148.1 23/21 166.1 > 133.0 43.37 ± 5.41 Amphetamine-D11 
Norepehedrine 21/11 152.1 > 134.1 21/19 152.1 > 117.1 64.26 ± 7.56 Amphetamine-D11 
         
Internal standards         
Cocaine-D3 40/20 307.2 > 185.1       
Benzoylecgonine-D8 38/19 298.2 > 171.1       
Cocaethylene-D8 38/20 326.2 > 204.2       
Amphetamine-D11 18/8 147.2 > 130.1       
Methamphetamine-D14 24/19 164.2 > 98.1       
MDA-D5 21/11 185.1 > 168.1       
MDMA-D5 26/13 199.1 > 165.1       
MBDB-D5 26/20 213.1 > 136.1       
MDEA-D5 28/13 213.1 > 163.0       
Caffeine-D9 38/15 204.2 > 144.1       
Nicotine-D4 37/20 167.1 > 134.1       
LSD-D3 41/24 327.2 > 226.1       
Heroin-D9 51/50 379.2 > 165.8       
Oxycodone-D6 36/29 322.2 > 247.1       
Morphine-D6 53/38 292.2 > 171.1       
Methadone-D9 31/15 319.3 > 268.2       
EDDP-D3 50/29 281.2 > 234.1       
Fentanyl-D5 44/38 342.2 > 105.1       
Codeine-D6 52/28 306.2 > 218.1       
Dihydrocodeine-D6 53/33 308.2 > 202.1       
Buprenorphine-D4 69/45 472.4 > 88.1       
Propoxyphene-D11 19/8 351.3 > 277.2       
Norpropoxyphene-D5 15/7 331.2 > 257.2       
Temazepam-D5 37/21 306.7 > 260.1       
Diazepam-D5 54/27 290.1 > 154.1       
Oxazepam-D5 38/21 292.0 > 246.0       
Fluoxetine-D6 25/8 316.2 > 154.1       
PCP-D5 18/14 249.2 > 164.1       
Ketamine-D4 31/27 242.1 > 129.1       
Mescaline-D9 46/12 221.2 > 204.2       
Methaqualone-D7 58/27 258.2 > 139.1             
aCV, cone voltage (V); CE, collision energy (eV) 
b MRM ratio : MRM1/MRM2 ratio calculated in surface water spiked before extraction with the ratio over the calibration range averaged 
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Table S3 – Performance data for compounds (intra- and inter-day instrumental repeatability) 
Compound Instrumental precision
a
                   
 Intra-day RSD% (n=6)          Inter-day RSD% (n=3) 
 0.5 (µg L
-1
)  50 (µg L
-1
)  500 (µg L
-1
)  1000 (µg L
-1
)  0.5 (µg L
-1
) 50 (µg L
-1
) 500 (µg L
-1
) 1000 (µg L
-1
) 
  D1 D2 D3   D1 D2 D3   D1 D2 D3   D1 D2 D3           
Stimulants and their metabolites                     
Cocaine 3.8 3.4 3.5  0.4 0.8 1.8  1.6 2.9 0.4  1.6 1.8 0.8  5.0 0.7 0.9 2.0 
Benzoylecgonine 2.7 4.4 7.3  2.2 2.8 1.3  1.4 1.5 1.2  0.9 1.0 1.2  6.2 1.7 0.7 0.3 
Norbenzoylecgonine 3.4 2.9 7.5  2.1 2.1 2.0  1.5 1.0 1.4  Out of linearity range
b
  1.2 0.8 0.7 OLR
b
 
Norcocaine 4.0 2.9 5.4  3.1 2.1 0.8  1.0 1.9 1.7  2.0 2.9 1.5  6.3 1.2 0.6 3.4 
Cocaethylene 5.1 2.8 4.1  2.3 2.2 1.5  0.7 1.0 1.6  Out of linearity range
b
  4.6 0.6 0.3 OLR
b
 
Anhydroecgonine methyl ester 7.0 10.9 8.7  1.4 2.6 3.2  1.4 1.2 3.2  Out of linearity range
b
  2.9 2.6 1.4 OLR
b
 
Ecgonidine  6.0 8.8 7.9  1.5 3.5 1.8  1.2 0.9 2.4  Out of linearity range
b
  3.0 2.6 0.3 OLR
b
 
Amphetamine   3.9 2.5 3.8  4.1 3.4 3.2  1.4 2.5 4.1  1.8 3.8 1.7  2.0 4.9 0.8 3.0 
Methamphetamine  5.7 3.7 3.9  4.7 3.9 1.9  2.0 2.8 2.9  1.2 2.7 2.7  1.5 2.3 1.0 1.2 
Methcathinone 6.2 4.5 4.3  4.4 4.9 4.5  1.9 3.6 2.0  2.2 3.5 1.4  2.5 3.6 0.1 0.1 
Benzylpiperazine (BZP) <IQL < IQL < IQL  4.3 1.7 4.1  1.9 1.1 2.8  2.4 1.0 2.6  <IQL 6.1 7.3 5.6 
Trifluoromethylphenylpiperazine (TFMPP) 5.7 4.5 4.6  2.6 3.0 2.8  1.8 1.3 1.0  2.7 2.5 2.0  3.0 2.4 4.4 4.5 
                     
Hallucinogens and their metabolites                    
MDA  7.7 4.5 3.4  5.9 2.4 2.5  2.3 2.0 2.4  1.1 2.0 2.5  3.9 2.3 1.1 1.1 
MDMA (Ecstasy) 3.9 3.8 3.6  2.7 3.3 3.8  1.5 2.4 2.7  1.9 1.5 1.2  4.4 2.0 1.8 0.4 
MDEA (MDE) 2.3 3.2 5.1  1.1 1.4 2.9  1.6 1.1 1.5  2.9 1.0 0.8  5.1 0.4 1.2 1.8 
MBDB 7.9 4.8 4.3  2.1 1.2 1.9  1.3 0.9 1.7  1.9 1.7 3.0  7.2 9.6 10.3 10.8 
BDB 3.7 3.9 6.0  1.8 1.6 2.7  Out of linearity range
b
  Out of linearity range
b
  9.5 1.4 OLR
b
 OLR
b
 
Mescaline < IQL < IQL < IQL  1.9 1.0 2.3  2.0 1.7 1.1  2.4 1.8 2.4  <IQL 1.0 0.4 2.5 
LSD 7.7 4.5 3.0  1.5 1.5 1.1  3.2 1.5 1.4  0.8 2.2 2.5  5.5 1.3 0.7 1.2 
O-H-LSD 7.7 4.8 2.9  1.2 1.0 0.9  2.0 1.4 0.9  2.1 1.9 1.5  2.3 2.2 2.5 0.2 
                     
Human indicators                    
Caffeine 3.9 6.0 5.5  4.8 2.4 2.6  1.8 2.9 2.5  2.4 4.8 1.8  0.6 4.5 2.6 3.5 
1,7-dimethylxanthine 6.2 2.1 4.2  4.9 1.6 3.2  3.6 4.3 1.0  2.7 4.8 1.5  0.8 7.9 4.7 2.6 
Nicotine 5.9 4.3 8.9  2.2 3.3 2.6  2.4 2.5 3.0  3.0 3.0 1.1  5.6 2.2 2.4 0.4 
Continine < IQL < IQL < IQL  2.1 1.2 3.0  2.9 3.0 2.2  Out of linearity range
b
  <IQL 0.9 1.6 OLR
b
 
Creatinine < IQL < IQL < IQL  2.0 2.1 3.2  2.2 3.4 2.5  0.9 3.1 2.7  <IQL 1.7 2.3 2.9 
                     
Opiods, morphine derivatives and their metabolites                   
Heroin 6.1 4.7 3.0  3.1 1.3 1.1  1.3 1.2 1.3  1.4 1.1 1.7  4.8 2.2 1.4 0.4 
6-acetylmorphine 2.1 4.2 4.8  2.4 1.8 1.1  2.4 1.8 1.1  2.5 0.5 2.6  0.8 0.2 1.1 2.6 
Codeine 9.1 4.6 5.8  1.9 2.1 2.3  1.4 2.4 1.7  1.9 2.0 3.1  1.3 2.9 0.9 2.0 
Norcodeine 8.6 4.4 5.0  1.8 1.7 3.1  1.9 2.0 2.0  2.2 1.1 3.5  4.7 2.5 1.6 1.6 
Oxycocodone 2.7 5.2 4.0  2.6 2.5 2.9  2.8 1.7 2.7  Out of linearity range
b
  4.2 0.9 2.0 OLR
b
 
Oxymorphone 7.9 3.5 4.6  1.2 3.2 2.4  2.1 2.1 2.8  Out of linearity range
b
  2.8 1.8 1.2 OLR
b
 
Morphine 6.6 5.0 3.8  3.4 2.8 2.6  3.4 1.3 3.8  2.7 4.3 3.2  4.5 1.9 0.7 3.1 
Normorphine 7.7 8.5 12.7  6.0 2.6 2.0  3.2 2.4 3.0  3.8 4.4 2.6  10.0 2.9 0.4 1.2 
Dihydrocodeine 8.6 3.1 4.8  1.4 1.6 1.1  0.7 1.1 1.0  1.1 1.2 1.3  3.2 0.3 0.6 0.3 
Buprenorphine 8.2 6.9 3.6  2.0 0.9 3.8  1.1 1.0 2.2  1.2 1.5 0.8  4.4 2.4 1.5 0.8 
Norbuprenorphine 5.2 5.6 6.1  2.1 2.6 1.3  1.4 1.6 3.6  Out of linearity range
b
  4.8 1.2 0.1 OLR
b
 
Methadone 2.5 4.9 3.9  1.3 1.1 1.8  2.6 1.6 1.9  Out of linearity range
b
  5.9 1.4 1.6 OLR
b
 
EDDP 3.3 4.7 8.4  2.8 1.0 1.8  3.7 3.2 3.3  0.4 3.0 2.0  5.3 0.2 1.4 1.6 
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EMDP 3.1 4.0 3.4  2.6 4.0 2.0  0.9 0.2 1.0  Out of linearity range
b
  5.1 2.3 1.2 OLR
b
 
Fentanyl 2.7 3.6 5.2  2.1 2.3 2.2  2.1 1.7 2.6  Out of linearity range
b
  0.2 0.9 0.8 OLR
b
 
Norfentanyl 4.1 4.2 2.9  1.2 3.2 2.9  2.6 1.7 3.3  Out of linearity range
b
  2.0 2.6 1.8 OLR
b
 
Propoxyphene  6.2 9.0 3.9  5.8 0.8 4.6  1.7 1.8 1.5  2.0 3.8 1.9  5.7 1.8 0.7 0.4 
Norpropoxyphene < IQL < IQL < IQL  4.0 5.6 3.2  2.6 5.1 3.5  2.4 1.5 3.8  <IQL 2.4 2.2 2.3 
Tramadol 6.0 4.5 2.6  1.9 2.3 2.0  2.3 2.0 1.7  2.7 1.4 3.9  4.7 1.2 0.7 2.5 
Nortramadol < IQL < IQL < IQL  5.4 4.3 4.3  4.7 4.5 4.4  Out of linearity range
b
  <IQL 3.9 2.6 OLR
b
 
                     
Benzodiazpines and their metabolites                    
Temazepam 5.9 7.1 3.9  1.6 2.4 0.9  3.8 3.5 1.5  Out of linearity range
b
  2.4 1.3 2.3 OLR
b
 
Diazepam  4.1 7.1 2.7  1.8 1.8 1.1  2.2 1.5 1.5  0.8 0.4 2.2  4.4 0.4 0.4 1.7 
Nordiazepam  7.1 8.3 4.8  2.2 1.7 1.6  1.1 2.0 1.6  1.9 1.5 1.1  7.3 6.5 6.0 3.0 
Nitrazepam 7.8 9.2 7.0  2.6 1.6 4.8  1.4 1.2 3.4  Out of linearity range
b
  7.3 1.0 3.9 OLR
b
 
7-aminonitrazepam 8.8 9.0 3.9  2.7 1.8 1.8  3.7 3.6 2.6  Out of linearity range
b
  7.2 10.4 6.8 OLR
b
 
Oxazepam 4.8 2.7 3.5  1.5 2.9 2.0  1.2 1.4 1.9  1.2 1.1 1.0  4.5 3.1 1.8 0.4 
Chlordiazepoxide 6.8 8.4 4.9  4.5 2.5 3.6  1.1 1.5 1.1  0.9 2.5 1.8  5.8 6.2 0.8 0.2 
                     
Antidepressants and their metabolites                    
Dosulepin 4.1 7.2 5.7  3.6 3.9 3.5  4.3 3.1 4.2  1.8 2.5 2.6  8.0 0.5 1.5 2.1 
Amitriptyline 5.6 3.6 6.1  2.0 1.4 1.8  3.4 4.2 3.8  1.6 3.6 2.8  6.6 1.5 0.2 0.6 
Nortriptyline 4.0 2.1 6.9  2.5 1.4 1.8  3.7 3.6 4.4  1.4 2.1 2.9  6.9 0.8 1.8 3.1 
Fluoxetine 9.8 9.8 11.9  1.5 4.2 3.3  1.6 1.0 1.0  2.7 2.4 1.8  10.8 2.0 2.4 2.8 
Norfluoxetine 5.5 5.4 3.7  5.3 2.4 3.7  Out of linearity range
b
  Out of linearity range
b
  6.9 3.7 OLR
b
 OLR
b
 
Venlafaxine 9.1 2.9 2.8  2.5 3.1 4.0  3.5 2.7 1.8  1.7 2.4 2.7  3.9 2.2 2.8 1.1 
                     
Dissociative anesthetics and their metabolites                   
Phencyclidine  7.2 5.6 5.5  2.9 3.5 2.3  1.1 1.3 3.0  1.8 1.9 2.8  2.9 1.5 0.5 3.3 
Ketamine  5.2 6.7 4.2  1.7 0.8 0.9  1.6 1.1 1.6  1.9 2.3 1.4  3.3 2.2 0.6 1.3 
Norketamine  4.3 5.8 6.9  2.0 1.0 1.9  1.4 1.1 0.5  2.4 2.3 1.2  4.3 0.8 1.0 1.4 
                     
Other                     
Methaqualone 2.1 3.4 2.3  2.3 4.6 1.9  Out of linearity range
b
   Out of linearity range
b
  4.3 2.6 OLR
b
 OLR
b
 
Sildenafil (viagra) < IQL < IQL < IQL  3.4 1.9 0.8  Out of linearity range
b
  Out of linearity range
b
  <IQL 0.9 0.9 OLR
b
 
                     
Drug precursors                    
Ephedrine/Pseudoephedrine  < IQL < IQL < IQL  6.2 1.6 3.3  2.4 1.9 2.4  2.9 3.0 3.1  <IQL 3.2 1.5 1.9 
Norepehedrine < IQL < IQL < IQL   5.7 3.7 3.3   3.1 2.6 1.1   Out of linearity range
b
   <IQL 3.6 1.5 OLR
b
 
a Sample diluent spiked with all compounds 
b Out of linearity range (OLR): Concentration higher than calibration range, see table 1 
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Table S4 – Performance data for compounds (intra- and inter-day method repeatability) 
Compound Method Precision
a
         
 Intra-day RSD% (n=3)  Inter-day RSD% (n=3) 
 0.5 (ng L
-1
)  50 (ng L
-1
)  1000 (ng L
-1
)  0.5 (ng L
-1
) 50 (ng L
-1
) 1000 (ng L
-1
) 
  D1 D2 D3   D1 D2 D3   D1 D2 D3         
Stimulants and their metabolites                
Cocaine 6.5 5.4 7.6  2.1 3.9 1.7  Out of linearity range
b
  4.5 3.7 OLR
b
 
Benzoylecgonine 5.5 5.1 3.8  1.4 5.6 1.8  Out of linearity range
b
  5.8 2.8 OLR
b
 
Norbenzoylecgonine 5.7 3.7 6.9  2.7 1.8 2.2  Out of linearity range
b
  6.5 1.3 OLR
b
 
Norcocaine 9.2 8.6 10.9  2.3 2.8 4.4  2.2 3.0 2.4  5.9 3.4 1.9 
Cocaethylene 6.3 5.3 5.4  1.8 2.1 2.0  Out of linearity range
b
  5.7 2.9 OLR
b
 
Anhydroecgonine methyl ester <MQL <MQL <MQL  2.6 3.7 2.7  Out of linearity range
b
  <MQL 2.5 OLR
b
 
Ecgonidine  <MQL <MQL <MQL  8.2 9.9 4.5  Out of linearity range
b
  <MQL 5.6 OLR
b
 
Amphetamine   <MQL <MQL <MQL  3.4 8.4 6.6  3.6 2.9 6.3  <MQL 10.0 5.1 
Methamphetamine  12.8 13.4 12.0  3.2 5.5 3.9  3.1 2.0 4.0  8.3 4.1 4.1 
Methcathinone <MQL <MQL <MQL  3.8 4.7 4.9  5.8 6.3 5.5  <MQL 7.2 3.3 
Benzylpiperazine (BZP) <MQL <MQL <MQL  3.4 3.5 4.3  Out of linearity range
b
  <MQL 3.8 OLR
b
 
Trifluoromethylphenylpiperazine (TFMPP) 12.0 6.5 8.9  7.3 4.0 4.6  Out of linearity range
b
  13.3 5.3 OLR
b
 
                
Hallucinogens and their metabolites                
MDA  11.6 7.0 10.6  3.2 3.5 2.3  4.4 3.5 3.0  11.0 2.1 3.0 
MDMA (Ecstasy) 5.6 8.9 6.7  2.9 1.7 3.5  2.8 1.9 2.7  9.4 3.9 3.2 
MDEA (MDE) 7.1 8.2 6.9  1.5 1.9 1.3  1.6 2.1 1.7  7.8 1.9 3.8 
MBDB 5.5 7.8 4.6  11.2 1.7 3.3  1.3 1.9 1.0  7.2 8.7 10.4 
BDB <MQL <MQL <MQL  3.2 2.8 3.4  1.1 1.1 1.6  <MQL 7.9 3.0 
Mescaline <MQL <MQL <MQL  1.6 2.1 2.4  0.9 5.2 1.6  <MQL 3.4 1.4 
LSD 14.1 12.1 7.8  3.0 1.5 3.7  2.1 1.8 1.2  12.7 1.9 2.1 
O-H-LSD 11.9 7.2 10.7  6.5 6.2 6.1  Out of linearity range
b
  8.3 9.8 OLR
b
 
                
Human indicators                
Caffeine <MQL <MQL <MQL  <MQL <MQL <MQL  12.7 13.0 13.3  <MQL <MQL 13.5 
1,7-dimethylxanthine <MQL <MQL <MQL  <MQL <MQL <MQL  13.4 16.4 12.3  <MQL <MQL 15.2 
Nicotine <MQL <MQL <MQL  2.9 3.6 3.2  2.1 1.9 2.7  <MQL 2.5 2.1 
Continine <MQL <MQL <MQL  4.8 3.0 3.7  Out of linearity range
b
  <MQL 2.2 OLR
b
 
                
Opiods, morphine derivatives and their metabolites               
Heroin <MQL <MQL <MQL  2.9 2.8 1.8  2.2 2.7 1.8  <MQL 4.1 2.1 
6-acetylmorphine 10.8 11.6 12.9  2.7 4.4 3.7  1.9 2.4 3.3  9.2 5.4 3.6 
Codeine 10.5 13.2 10.6  1.8 1.5 2.4  1.8 2.0 2.5  8.4 1.7 2.2 
Norcodeine <MQL <MQL <MQL  2.6 3.5 2.2  2.6 2.3 3.5  <MQL 3.9 4.4 
Oxycocodone 14.8 12.4 13.4  3.6 4.4 2.3  Out of linearity range
b
  10.7 1.9 OLR
b
 
Oxymorphone 11.9 7.3 10.0  6.9 5.3 8.9  Out of linearity range
b
  10.4 9.3 OLR
b
 
Morphine <MQL <MQL <MQL  5.2 6.5 7.7  2.6 3.9 6.0  <MQL 8.3 5.6 
Normorphine <MQL <MQL <MQL  5.3 5.4 7.4  3.8 4.4 6.2  <MQL 7.4 6.4 
Dihydrocodeine 9.0 5.9 13.3  1.9 1.9 0.9  1.1 2.1 1.2  8.2 1.2 1.8 
Buprenorphine <MQL <MQL <MQL  4.2 3.4 3.2  2.5 1.0 1.5  <MQL 3.8 1.4 
Norbuprenorphine <MQL <MQL <MQL  4.4 5.0 4.7  Out of linearity range
b
  <MQL 4.3 OLR
b
 
Methadone 3.7 5.1 3.6  2.4 2.0 3.4  Out of linearity range
b
  3.1 2.4 OLR
b
 
EDDP 7.9 2.9 5.2  3.4 3.1 4.7  2.9 2.3 3.7  5.7 5.9 4.1 
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EMDP 6.7 7.3 5.4  2.2 3.6 3.7  Out of linearity range
b
  6.8 6.5 OLR
b
 
Fentanyl 4.7 6.5 11.4  1.1 2.4 3.0  Out of linearity range
b
  6.2 2.2 OLR
b
 
Norfentanyl 6.3 6.2 10.4  2.4 3.1 3.8  Out of linearity range
b
  6.0 2.7 OLR
b
 
Propoxyphene  <MQL <MQL <MQL  3.3 1.8 3.2  3.0 3.5 1.9  <MQL 1.7 2.1 
Norpropoxyphene <MQL <MQL <MQL  6.6 6.7 5.5  2.1 3.4 3.1  <MQL 9.3 5.4 
Tramadol <MQL <MQL <MQL  1.9 2.0 3.0  1.7 4.0 3.1  <MQL 3.1 3.9 
Nortramadol <MQL <MQL <MQL  12.5 7.1 14.5  Out of linearity range
b
  <MQL 16.5 OLR
b
 
                
Benzodiazpines and their metabolites                
Temazepam <MQL <MQL <MQL  5.9 4.7 4.7  Out of linearity range
b
  <MQL 5.7 OLR
b
 
Diazepam  5.1 5.9 6.7  2.2 1.1 1.2  1.4 1.4 1.4  6.4 2.2 1.6 
Nordiazepam  7.6 9.5 13.1  3.3 3.1 2.8  1.9 2.4 1.9  9.9 11.9 6.2 
Nitrazepam <MQL <MQL <MQL  10.8 12.6 11.4  Out of linearity range
b
  <MQL 14.1 OLR
b
 
7-aminonitrazepam <MQL <MQL <MQL  2.1 6.9 4.5  Out of linearity range
b
  <MQL 9.9 OLR
b
 
Oxazepam 6.4 14.8 14.3  2.6 1.5 3.5  1.4 1.4 1.8  12.5 3.2 1.6 
Chlordiazepoxide 12.1 11.9 10.7  3.0 3.8 3.1  2.8 3.2 2.0  12.0 7.1 2.2 
                
Antidepressants and their metabolites                
Dosulepin 12.2 14.7 7.7  5.9 7.7 7.7  Out of linearity range
b
  12.5 11.2 OLR
b
 
Amitriptyline 12.9 7.7 15.0  7.6 8.0 8.6  Out of linearity range
b
  8.5 12.0 OLR
b
 
Nortriptyline 8.0 9.9 9.6  6.5 8.5 8.4  Out of linearity range
b
  5.6 12.7 OLR
b
 
Fluoxetine <MQL <MQL <MQL  3.4 5.0 2.3  2.2 2.5 1.4  <MQL 3.5 1.6 
Norfluoxetine <MQL <MQL <MQL  3.2 3.9 6.9  Out of linearity range
b
  <MQL 7.6 OLR
b
 
Venlafaxine 12.2 13.1 7.1  3.0 3.1 2.9  Out of linearity range
b
  9.6 3.8 OLR
b
 
                
Dissociative anesthetics and their metabolites                
Phencyclidine  8.9 10.3 8.2  7.7 5.1 4.9  2.9 2.2 3.7  9.7 5.7 2.5 
Ketamine  5.5 5.2 6.6  1.4 2.1 1.4  1.5 1.8 0.6  6.1 1.5 1.8 
Norketamine  12.7 8.9 13.4  1.5 1.8 1.8  2.3 2.1 2.0  11.1 2.4 1.7 
                
Other                
Methaqualone 5.1 3.7 4.9  3.0 3.5 2.6  Out of linearity range
b
  4.3 4.6 OLR
b
 
Sildenafil (viagra) <MQL <MQL <MQL  5.0 3.7 6.7  Out of linearity range
b
  <MQL 4.5 OLR
b
 
                
Drug precursors                
Ephedrine/Pseudoephedrine  <MQL <MQL <MQL  8.2 11.9 6.4  2.9 5.0 5.5  <MQL 10.7 4.4 
Norepehedrine <MQL <MQL <MQL   6.6 10.1 11.2   Out of linearity range
b
   <MQL 13.1 OLR
b
 
a Surface water spiked with compounds before extraction 
b Out of linearity range (OLR): Concentration higher than calibration range, see table 1 
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Table S5 – Performance data for compounds (method accuracy) 
Compounds  Method accuracy RSD%
a
 
 0.5 (ng L
-1
)    50 (ng L
-1
)      1000 (ng L
-1
)   
  S1 S2 S3   S1 S2 S3   S1 S2 S3 
Stimulants and their metabolites            
Cocaine 4.7 5.8 0.3  1.0 0.9 -0.7  Out of Linearity range
b
 
Benzoylecgonine 10.0 7.5 8.1  5.9 5.6 1.9  Out of Linearity range
b
 
Norbenzoylecgonine -1.7 10.1 10.1  0.6 0.1 0.8  Out of Linearity range
b
 
Norcocaine 21.5 14.5 8.3  8.3 5.4 8.2  -7.1 -6.3 -4.4 
Cocaethylene 9.5 11.0 10.3  6.5 4.9 2.4  Out of Linearity range
b
 
Anhydroecgonine methyl ester <MQL <MQL <MQL  10.0 8.6 9.0  Out of Linearity range
b
 
Ecgonidine  <MQL <MQL <MQL  4.1 6.3 4.6  Out of Linearity range
b
 
Amphetamine   1.1 -2.0 -1.8  -7.8 -6.4 -18.0  -2.7 -5.8 -7.2 
Methamphetamine  1.6 17.1 -6.3  -0.5 -1.7 -1.4  -4.3 -4.0 -5.1 
Methcathinone -15.7 -19.9 -19.5  17.3 18.9 20.4  -5.7 4.7 9.2 
Benzylpiperazine (BZP) <MQL <MQL <MQL  3.8 0.6 6.8  Out of Linearity range
b
 
Trifluoromethylphenylpiperazine (TFMPP) -0.3 18.2 23.7  28.7 27.6 22.9  Out of Linearity range
b
 
            
Hallucinogens and their metabolites            
MDA  -0.1 -4.7 2.3  -4.7 -3.7 -3.8  0.6 0.2 -3.0 
MDMA (Ecstasy) -3.0 -0.4 -3.1  0.4 -3.0 -3.2  -2.1 -3.3 -3.9 
MDEA (MDE) 2.3 7.7 -1.3  -2.1 -2.8 -5.3  -4.6 -8.1 -8.7 
MBDB -3.5 -6.9 -11.5  -4.5 -4.7 -7.9  -0.1 -0.5 -1.4 
BDB <MQL <MQL <MQL  -22.6 -20.6 -25.0  1.4 -2.5 -6.7 
Mescaline <MQL <MQL <MQL  8.3 5.4 1.1  -1.9 -1.7 -3.9 
LSD 3.5 4.1 1.1  -5.8 -5.8 -8.7  -8.8 -8.7 -9.8 
O-H-LSD -2.7 0.9 12.1  -17.1 -6.0 2.7  Out of Linearity range
b
 
            
Human indicators            
Caffeine <MQL <MQL <MQL  <MQL <MQL <MQL  -4.0 15.1 7.0 
1,7-dimethylxanthine <MQL <MQL <MQL  2.9 11.0 3.7  -11.1 2.5 -2.4 
Nicotine <MQL <MQL <MQL  0.8 1.1 2.7  -5.7 -2.8 -3.8 
Continine <MQL <MQL <MQL  -14.0 -14.1 -11.9  Out of Linearity range
b
 
            
Opiods, morphine derivatives and their metabolites           
Heroin <MQL <MQL <MQL  7.7 3.2 2.4  -10.6 -11.0 -12.6 
6-acetylmorphine 1.1 -0.6 -2.3  -6.2 -14.8 -16.6  1.9 -2.7 -2.1 
Codeine 0.8 10.3 10.3  -2.5 -4.2 -3.2  0.1 -3.5 -3.0 
Norcodeine 20.8 23.0 16.0  -18.7 -19.4 -19.5  5.3 -2.6 -2.6 
Oxycocodone -5.6 21.6 -2.2  2.5 5.6 2.6  Out of Linearity range
b
 
Oxymorphone -7.3 8.5 9.1  17.0 16.1 17.3  Out of Linearity range
b
 
Morphine 0.0 0.0 0.0  8.9 16.2 2.0  7.7 8.2 5.2 
Normorphine <MQL <MQL <MQL  7.7 2.7 -2.1  -5.0 -3.3 -6.2 
Dihydrocodeine 8.5 5.6 3.6  2.9 4.9 3.8  -0.4 0.4 -0.2 
Buprenorphine <MQL <MQL <MQL  0.2 -5.2 -0.4  0.6 2.4 2.1 
Norbuprenorphine <MQL <MQL <MQL  -10.6 -8.0 -4.9  Out of Linearity range
b
 
Methadone 21.9 22.7 18.3  9.9 11.9 9.6  Out of Linearity range
b
 
EDDP 8.2 1.6 -4.7  -16.8 -19.4 -24.1  -1.3 -5.9 -2.6 
EMDP -5.6 -11.7 -1.5  -14.9 -9.3 -1.0  Out of Linearity range
b
 
Fentanyl 17.5 21.0 21.9  14.0 17.5 13.1  Out of Linearity range
b
 
Norfentanyl -28.1 -24.9 -22.9  -2.5 -2.6 -3.8  Out of Linearity range
b
 
Propoxyphene  -24.6 -18.6 -25.0  1.2 3.2 2.1  -5.6 -8.3 -9.5 
Norpropoxyphene <MQL <MQL <MQL  -6.2 14.8 23.9  -22.7 -22.7 -18.2 
Tramadol 11.2 11.9 12.5  11.4 10.5 13.7  -5.3 -11.8 -10.6 
Nortramadol <MQL <MQL <MQL  -14.7 -28.2 -33.1  Out of Linearity range
b
 
            
Benzodiazpines and their metabolites            
Temazepam <MQL <MQL <MQL  4.5 1.0 -2.4  Out of Linearity range
b
 
Diazepam  10.7 7.9 5.5  9.6 7.7 6.2  -1.7 -3.2 -2.6 
Nordiazepam  10.2 -9.1 -22.5  -5.4 -19.2 -27.3  -3.6 -11.6 -18.7 
Nitrazepam 11.4 9.5 -9.9  -11.3 -26.7 -20.5  Out of Linearity range
b
 
7-aminonitrazepam <MQL <MQL <MQL  -26.4 -24.1 -28.3 
 
 Out of Linearity range
b
 
Oxazepam -1.7 -0.1 9.2  6.1 0.8 1.8  -2.8 -6.2 -7.0 
Chlordiazepoxide -6.9 -4.5 -5.9  1.1 -5.8 -6.6  -8.6 -7.1 -8.1 
            
Antidepressants and their metabolites             
Dosulepin 21.1 21.5 2.2  18.5 27.3 12.6  Out of Linearity range
b
 
 30 
Amitriptyline 19.5 23.9 4.7  26.0 17.2 13.4  Out of Linearity range
b
 
Nortriptyline 29.3 29.2 12.7  30.1 21.8 13.5  Out of Linearity range
b
 
Fluoxetine <MQL <MQL <MQL  -2.9 1.1 -2.3  -1.6 -4.4 -4.2 
Norfluoxetine <MQL <MQL <MQL  -0.7 -4.4 -6.9  Out of Linearity range
b
 
Venlafaxine 0.6 -5.3 10.7  -8.3 -8.5 -11.6  Out of Linearity range
b
 
            
Dissociative anesthetics and their metabolites           
Phencyclidine  3.1 8.9 3.0  3.9 -3.5 -5.0  -10.4 -11.0 -13.6 
Ketamine  14.3 19.7 10.3  2.4 3.2 3.0  0.6 -1.4 0.7 
Norketamine  -4.9 5.3 7.3  -1.7 -0.4 -3.5  -3.3 -1.0 1.4 
            
Other            
Methaqualone 7.3 4.5 2.0  -3.9 -5.8 -10.0  Out of Linearity range
b
 
Sildenafil (viagra) <MQL <MQL <MQL  15.2 8.6 15.3  Out of Linearity range
b
 
            
Drug precursors            
Ephedrine/Pseudoephedrine  <MQL <MQL <MQL  4.1 2.1 -7.3  1.5 0.6 3.5 
Norepehedrine <MQL <MQL <MQL   -11.2 -19.5 -22.4   Out of Linearity range
b
 
a Surface water spiked with compounds before extraction  
b Out of linearity range: Concentration higher than calibration range, see table 1 
 
 
